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Abstract
A variety of therapeutic proteins have shown potential to treat central nervous system (CNS)
disorders. Challenge to deliver these protein molecules to the brain is well known. Proteins
administered through parenteral routes are often excluded from the brain because of their poor
bioavailability and the existence of the blood-brain barrier (BBB). Barriers also exist to proteins
administered through non-parenteral routes that bypass the BBB. Several strategies have shown
promise in delivering proteins to the brain. This review, first, describes the physiology and
pathology of the BBB that underscore the rationale and needs of each strategy to be applied.
Second, major classes of protein therapeutics along with some key factors that affect their delivery
outcomes are presented. Third, different routes of protein administration (parenteral, central
intracerebroventricular and intraparenchymal, intranasal and intrathecal) are discussed along with
key barriers to CNS delivery associated with each route. Finally, current delivery strategies
involving chemical modification of proteins and use of particle-based carriers are overviewed
using examples from literature and our own work. Whereas most of these studies are in the early
stage, some provide proof of mechanism of increased protein delivery to the brain in relevant
models of CNS diseases, while in few cases proof of concept had been attained in clinical studies.
This review will be useful to broad audience of students, academicians and industry professionals
who consider critical issues of protein delivery to the brain and aim developing and studying
effective brain delivery systems for protein therapeutics.
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Protein therapeutics has made significant progress during the past 30 years, beginning with
the invention of the first recombinant protein used in clinical practice, a human insulin [1].
Since then, development of protein therapeutics has been one of the biotech’s most notable
successes. In recent years, the number of protein-based therapeutics reaching the
marketplace has increased exponentially. As of today, more than 130 proteins or peptides
are used in clinics and many more are in development [2]. The currently marketed proteins
include enzymes, antibodies, clotting factors, anticoagulants, modern insulins, growth
hormone, follicle-stimulating hormone, hematopoietic growth factors, interferons,
interleukins and others. The market of the therapeutic proteins holds tremendous potential
for future growth and it is estimated that by the end of 2018, it may reach the mark of US
$165 billion as new products may enter the sector. As patents on first-generation proteins
wind down, the industry seeks to protect their markets by introducing protein delivery
technologies that provide for improved stability, bioavailability and safety of the therapeutic
proteins. Such technologies aim to overcome obstacles to the clinical application of the
proteins due to a lack of desirable attributes for adequate absorption or distribution. It
therefore becomes critical to incorporate proteins in safe, stable and efficacious delivery
systems. Because proteins face formidable enzymatic and penetration barriers, efficient
protein delivery to its destination in the body remains a very challenging if not a formidable
task.
There is a tremendous potential to develop protein therapeutics for the treatment of
neurological and neurodegenerative disorders. Examples include Alzheimer’s disease (AD),
Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), human immunodeficiency
virus 1 (HIV-1)-associated dementia (HAD) (or more generally HIV-associated cognitive
dysfunction), multiple sclerosis (MS), lysosomal storage disorders (LSDs; Gaucher’s
disease, Niemann-Pick disease, Tay-Sachs disease and Sandhoff’s disease, Krabbe’s disease,
Fabry’s disease, metachromatic leukodystrophy amongst nearly 50 total disorders) and
others. Other diseases associated with the central nervous system (CNS) include brain
tumors, stroke, traumatic brain injury (TBI), and metabolic disorders. Some examples of
potential protein therapeutics to treat these CNS related disorders include enzymes in LSDs,
antibodies in AD and brain tumors, neurotrophic factors in PD and stroke, and gut-brain
hormones in obesity.
Clinical use of these proteins, however, is extremely challenging because of the unique and
complex environment imposed by the CNS. Systemic delivery of proteins to the brain
inevitably encounters two major hurdles: the rapid serum clearance and the limited
penetration at the blood-brain barrier (BBB). Some protein molecules, such as neurotrophic
factors can cross the BBB to some extent but are rapidly cleared from the blood, whereas
others, such as antibodies, are stable and long circulating in blood but absolutely not
permeable at the BBB. In both cases systemic delivery of proteins does not allow to attain
their sufficient brain concentration for effective treatment. Proteins can also access the brain
through alternative delivery routes that allow bypassing the BBB, such as
intracerebroventricular (i.c.v.), intraparenchymal, intranasal (i.n.) or intrathecal (i.t.)
administration. However, in most cases the brain uptake of proteins following such
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administration routes is still surprisingly low, especially in the targeted brain regions where
protein therapeutics needs to be delivered. It has been gradually accepted that serious
biological barriers are associated with each of these alternative delivery routes.
Therefore a great deal of effort has been dedicated to developing the drug delivery systems
and approaches that could help protein molecules crossing numerous barriers on their way to
the site of action in the brain. Multiple drug delivery strategies were explored in the attempts
to address this challenge. For example, chemical modification of proteins with poly(ethylene
glycol) (PEG), known as PEGylation [3], or incorporation of proteins into poly(D,L-lactic-
co-glycolide) (PLGA) particles [4, 5] increased stability and bioavailability of certain
proteins and resulted in development of the Food and Drug Administration (FDA) approved
products for various peripheral diseases. However, neither of these technologies has shown
much promise so far in delivering protein therapeutics to the brain for treatment of CNS
related diseases. Several specific molecules (antibodies, peptides, etc.) that can target and
cross BBB through intrinsic transport systems available in brain endothelium were identified
and conjugated to protein of interest to create targeted therapeutic agents for CNS related
diseases. However, no such conjugate has progressed far enough to enter clinical trials
although similar conjugates with small molecule drugs seem to be somewhat more advanced
(e.g. paclitaxel-Bp-2 ANG1005, Angichem, Inc). Some of the studies in this area go back
nearly 30 years, and yet during this considerable period, despite consistent and steady effort
by numerous capable researchers across the globe relatively little progress was achieved,
which only underscores the enormity of the task.
However, analysis of previous experience in this field along with understanding of the
recent achievements and trends in the drug delivery and nanomedicine science allow us to
suggest that a new explosive development is just behind the corner. We believe that
investigators should expect a very exciting journey during the next decade in pursuit of
novel CNS technologies and therapeutics and that a critical mass of knowledge has been
reached enabling new principal breakthroughs. In anticipation of this development we
decided to critically analyze the past experiences from the current prospective that in our
view in essential to achieve success in this field. We believe that the recent dramatic
improvement in understanding the molecular physiology of CNS environment and the
various barriers that exist on the way of successful protein delivery to the brain will be
conductive to future progress. There is growing realization that the BBB, as part of the
neurovascular unit (NVU), represents an interactive, dynamic, regulatory interface between
the CNS and peripheral tissues [6–15]. It is also clear that various pathological processes
associated with neurological and neurodegenerative disorders alter the NVU and cause BBB
dysfunction, which brings some opportunities and challenges to the design of protein
therapeutics for these disorders. The choice of the routes of administration of these
therapeutics is also pivotal and requires consideration of the disease stage (chronic or acute),
location within the brain (widespread or local), and chemical nature of the compound to be
delivered. We also believe, that there is a great opportunity in using nanomedicine
approaches to improve the site-specific delivery and brain regional distribution of proteins
administered though non-conventional routes allowing to avoid the BBB. It should be noted
that due to small amounts of substances that can enter the brain, robust and reliable
bioanalytical assays are needed for the analysis of the pharmacokinetics (PK) and
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biodistribution of the protein therapeutics. Carefully designed PK studies and proper
interpretation involving analysis of PK and pharmacodynamics correlations and dose-
responses are absolutely essential. Development of animal models that closely recapitulate
human diseases and understanding of the limitations of these models are needed to carefully
interpret results of the preclinical animal studies and use these results as for guidance for
clinical trials. Here we present the readers with this review which briefly and sequentially
considers the 1) BBB physiology and pathology in CNS related disorders; 2) main classes of
protein and peptide therapeutics for CNS; 3) delivery routes for protein therapeutics; 4)
chemical modification of proteins for CNS delivery; and 5) particle-based carriers for CNS
delivery of proteins. We hope to disseminate and advance an in-depth understanding of each
of these strategies and provide useful information for future design of protein delivery to the
brain.
2. BBB physiology and pathology in CNS related disorders
Discovery of BBB is usually ascribed to the work of Paul Ehrlich and Edwin Goldman over
a hundred years ago. They observed that intravenously injected dye stained all the organs
with the exception of the brain and that the same dye exclusively stained the brain after
injection into the brain [16, 17]. Thomas Reese and Morris Karnowsky further demonstrated
that the blood was separated from the brain at the level of brain microvessel endothelial cells
(BMECs). Under high resolution electron microscopy it was shown that intravenously
injected horseradish peroxidase (HRP), 43 kDa, stained only BMECs and the tight junctions
(TJ) between BMECs but was not detectable beyond the vascular endothelium [18, 19].
Accordingly, the physiological BBB generally refers to the continuous layer of BMECs [20]
(Figure 1). Different from the capillaries of peripheral tissues, BMECs are sealed by TJ,
virtually excluding paracellular transport of any molecule from blood to brain. It is also
characterized by 1) small number of vesicles at the luminal side of BMECs, 2) presence of
the drug efflux pumps at the basal luminal side, and 3) high metabolic activity responsible
for degradation of most internalized substances. Altogether these morphological and
functional features result in limited transcytosis and endocytosis and thus explain why BBB
acts as a formidable barrier for many substances to enter the brain. Adjacent to the brain
capillaries along the basal luminal are perivascular cells (also called pericytes) which are
now recognized to play important roles in the regulation of CNS homeostasis, the BBB
integrity, the macrophage activity and modulation of blood flow [21]. A thin basement
membrane (i.e. basal lamina) supports the abluminal surface of the endothelium surrounding
the endothelial cells and pericytes. Another important cell type involved in the BBB
function in the brain is astrocytes. One type of brain astrocytes completely envelops BMECs
and pericytes with their end feet and this structure initially was thought to play a substantial
role by aiding the maintenance of the BBB. However, more recent studies show that
astrocytes are more important in the regulation of water and ion homeostasis and secretion
of chemokines as a sensor of pathologic changes, which helps modulating the BBB function
[22]. Along with adjacent glia and neurons, BMECs, pericytes, and astrocytes comprise
NVU, a dynamic cellular interface that defines the functioning of the CNS [23].
Pathology of many neurological disorders, including AD and HIV-associated cognitive
dysfunction, as well as stroke, brain tumors, and TBI involves BBB dysfunction (Figure 1)
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[6–15]. Failure of the BBB due to alteration of the TJ in many cases, like stroke or TBI, is a
direct result of the disease pathology, while in other cases, like MS, it is a precipitous event
of the disease [23]. Sometimes, like in the case of AD the BBB contributes to disease onset
and progression and thus itself becomes a therapeutic target [24]. There are reports that the
BBB could be compromised and associated with the neuropathology and disease
deterioration in LSDs [13]. Disruption of the TJ of the BBB as a result of the disease-
induced hypoxia has been thoroughly investigated [25, 26]. Disease-induced inflammation
also contributes to the alteration of the BBB. Abnormal, monocyte migration across the
BBB to the brain is probably induced by a release of inflammatory cytokines during
pathological processes associated with the disease progression [27]. Structural and
morphological alterations in the NVU and BBB associated with the disease, such as basal
lamina degradation by metalloproteases in hemorrhagic transformation after human
ischemic stroke were also described [28, 29]. Likewise, during ALS the BBB impairment
was accompanied by a decreased mRNA expression of ZO-1 and occludin as well as agrin, a
basal membrane constituent [30]. Disease may also affect functional components of BBB
responsible for transport of various substances in and out of the brain. For example,
increased number of pinocytic vesicles in the BMECs has been described in certain cases
such as AD [31] HIV-related neuropathologies [32], some leukodystrophies [33], and
exposure of the brain to microwave radiation [34]. Both down and upregulation of the
expression of the P-glycoprotein (Pgp), a major outwardly drug efflux transporter at the
luminal membrane of BMECs was observed during brain inflammation, oxidative stress, and
HIV-1 infection [35]. In some cases the malfunction of the BBB transport systems is directly
linked to the disease cause. For example, in obese patients function of BBB transporter of
leptin, a peptide hormone that controls appetite and metabolism, is impaired. Leptin, is
produced by fat tissues and reaches its target in the brain by crossing BBB via specific,
saturable transport system in healthy individuals [36]. Inability to cross BBB is referred to as
leptin resistance and results in metabolic dysfunction, which needs to be overcome to deliver
sufficient amount of leptin to the brain [37–40].
Clearly, it is important to recognize and understand the pathological changes of the BBB
when designing the delivery system for protein therapeutics to access the brain. However,
one cannot simply rely on the breakdown of the BBB. First, not all neurological disorders
are characterized by BBB dysfunction. In rat model of parkinsonism no changes in BBB
functionality was observed and it was concluded that BBB dysfunction was not a specific
characteristic of this disease [41]. Second, even in the cases when the BBB opening as a
result of the disease was documented the extent of the opening remains unclear, as different
results were obtained using low molecular mass and polymeric probes [42–45]. Third, the
timing of the opening and its relation to the disease progression in many cases is not well
understood [46–49]. Both the extent of the BBB opening and the timing, may be dependent
on the disease progression and the animal model used to study these phenomena. For
example, it is well known that the brain tumor vasculature is characterized by altered BBB.
However, the nature and extent of these changes is defined by type of tumor. In low-grade
astrocytomas barrier properties of tumor endothelium are close to normal, while in high-
grade astrocytomas, glioblastomas, and brain metastases of systemic cancers the vasculature
is leaky and lacks differentiated transport properties of normal brain endothelium [50].
Yi et al. Page 5






















Finally, it is unclear whether the areas of the brain that become accessible due to the BBB
breakdown are really in need of delivery of a therapeutic agent, or if the therapies should be
delivered to the brain areas, which not affected by the disease pathology to the extent
resulting in the BBB compromise.
3. Main classes of protein and peptide therapeutics for CNS
Current efforts in development of CNS biotherapeutics have focused on several classes of
molecules including gut-brain hormones, lysosomal enzymes, neurotrophic factors,
antibodies, and peptides. Some of the proteins and peptides evaluated for various
neurological disorder indications in patients or approved for clinical use are listed in Table
1. All these molecules are believed to act upon targets in the CNS, which underscores the
importance of their delivery to the brain. One class is gut-brain hormones that are released
from the gut and exert their biological function partially or exclusively within the CNS.
These hormones along with circulating nutrients and neuronal peptides modulate appetite,
feeding and metabolism. Accordingly, they provide a range of therapeutic opportunities for
treatment of metabolic disorders (e.g. diabetes, obesity) [76]. All the gut-brain hormones are
acidic, less than 5 kDa in size (except for leptin, which is 16 kDa), they easily degrade and
rapidly clear from circulation through renal clearance. As a result they have poor
bioavailability after systemic administration, which otherwise would be most convenient and
acceptable for these treatment needs (chronic, non-life threatening diseases, multiple dosing,
patients self-use). Although hormones with peripheral site of action can certainly benefit
from increasing their circulation time, most gut-brain hormones need to cross the BBB to
exert physiological effect. In some cases, for example, leptin, the disease condition is
associated with the impairment of a normal physiological transport mechanism at the BBB
and therefore increasing permeability of such molecules at the BBB becomes crucial to
ensure physiological effect [77, 78].
Lysosomal enzymes represent another major category of proteins that need to be delivered
to the brain for treatment of LSDs that manifest neurological pathologies. There has been
considerable success in development of enzyme replacement therapies (ERT) of LSDs with
peripheral manifestations, such as type 1 Gaucher disease, Fabry disease, and Pompe disease
[79]. For such diseases FDA has approved at least nine systemically administered ERT
drugs. However, systemic therapies for LSDs associated with CNS pathologies appear to be
less effective possibly due to limited penetration of the potential therapeutic agents at the
BBB. Many lysosomal enzymes are homodimeric or heterodimeric glycoproteins of
relatively large molecular weight (>100 kDa). Almost all of them are tagged with mannose
6-phosphate (M6P) moieties, which ensure their lysosome sorting in the cells [80].
Unfortunately, the M6P-receptor is not expressed in brain endothelium in physiological
conditions and cannot be used to target proteins to the BBB [81–83]. To the contrary,
circulating enzymes are readily engulfed by macrophages via M6R receptor and thus are
rapidly cleared from the blood [84]. Fast clearance, large molecular weight, hydrophilic
nature arising from the attached glycans, and resulting inability to penetrate BBB are all
obstacles to effective delivery of lysosomal enzymes to the CNS through systemic routes.
Indeed one promising example of ERT for CNS related LSDs, evaluated in clinical trials
involves treatment of mucopolysaccharidosis II (MPS II) patients with iduronate-2-sulfatase
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(I2S) through i.t. administration [60, 61]. Therefore, bypassing the BBB by choosing an
appropriate administration route as discussed below could be a valuable approach to
delivery of such therapeutic agents.
Neurotrophic factors also known as “neurotrophins” represent family of proteins that are
responsible for the growth and survival of developing neurons and the maintenance of
mature neurons functionality. Examples include nerve growth factor (NGF), brain-derived
neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF), neurotrophin-3
(NT-3), fibroblast growth factor (FGF) and epidermal growth factor (EGF). These proteins
commonly carry a positive charge (pI > 8), have a molecular weight ranging from 5 to 30
kDa and exhibit potency at femtomolar to nanomolar concentrations [85]. Albeit
neurotrophins have long been explored as potential neuroregenerative and neuroprotective
therapeutic agents during various CNS-pathologies and some were tested in clinical trials,
none of them have emerged as regulatory approved medicines. Interestingly, an active
transport mechanism for some of neurotropic factors such as NGF, NGF and NT-3 does
exist at the BBB allowing for transport of systemic proteins to the brain [86, 87]. However,
these agents still face multiple challenges to CNS delivery that are common for most CNS
therapeutics, including low rapid enzymatic inactivation, multiple clearance processes,
sequestration by serum proteins and peripheral tissues, and immunogenicity. Furthermore,
there is an additional challenge due to a need of targeting a neurotrophic drug to a brain
region relevant to its pathology. Indeed neurotrophin receptors and signaling pathways are
spread throughout the brain where they play multiple physiological roles in impacting cell
death, plasticity and survival. Thus there is a possibility for off-target effects unless
neurotrophins are delivered precisely to their needed sites of action. On the other hand
missing the proper point of delivery could result in the lack of the needed activity.
Therefore, developing methods allowing for delivery of neurotrophins to specific brain
regions is especially important. Examples, include GDNF treatment of PD patients, where a
series of clinical trials have shown contradictory or negative effects possibly due to
insufficient penetration of this neurotrophin to its site of action [64, 65, 88] and new delivery
methods are designed specifically to address this challenge.
Brain delivery of antibodies is currently mainly investigated for treating AD and brain
tumors [89–93]. However, possibilities for antibody-based CNS therapeutics are enormous.
A relatively long serum half-life, high potency, and limited off-target toxicity are all very
desirable pharmacological advantages of antibodies for developing CNS therapeutics.
However, due to a large molecular mass (e.g. 150 kDa for IgG), antibodies are generally
restricted to extracellular space. Accordingly, whereas bioavailability is a much lesser
concern for antibody delivery compared to other proteins, low permeability of antibodies at
the BBB is a major issue that has been researched since early 1990s [94]. Some of the
approaches to antibody delivery are considered below in Section 5.4, but generally these
approaches has not yet not evolved to reach the clinical stage and efficient delivery of the
antibodies to the brain remains a major unmet medical need.
“Peptides” are short chains of amino acid monomers linked by amide bonds and are
considered here as a separate category due to their relatively small size (less than 20 amino
acids and molecular mass less than 5 kDa) and common lack of secondary structure. They
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can function as receptor agonists or antagonists by activating or blocking central signaling
pathways, and depending on the structure, can be used in treatment of numerous CNS
related disorders, such as, schizophrenia, anxiety, depression, autism and others. Therapeutic
peptides offer multiple advantages compared to small molecules: high specificity and
potency, minimal cross-reactivity, no tissue accumulation, efficient metabolism, limited
drug–drug interaction, minimal side effects and low immunogenicity. However, similar to
most proteins, peptides exhibit very short serum half-life (min. to hrs.), low serum stability
and poor permeability at the BBB, which hinder therapeutic use of these molecules for
treatment of CNS disorders. Attempts to address these issues have involved various
manipulations with the conformation and molecular structure of peptides as reviewed
elsewhere [95]. Moreover, unlike most proteins discussed herein some especially lipophilic
and short sequence peptides, are substrates of drug efflux transport system, Pgp
overexpressed at the BBB [96]. Therefore bypassing or inhibiting this transport system is
important for the successful delivery of such molecules.
Outside of the scope of this review are synthetic peptides and proteins used in vaccination,
some of which have shown considerable promise in treating CNS related diseases. For
example, a therapeutic vaccine, CDX-110 consisting of 14 amino acid peptide, rindopepimut
conjugated to immunostimulator molecule, keyhole limpet hemocyanin (KLH) can activate
anti-tumor immune response by targeting tumor-specific epidermal growth factor receptor,
EGF receptor (EGFR) vIII. Both preclinical and clinical studies demonstrated that following
intradermal injection, CDX-110 is effective in treating glioblastoma multiforme, the
deadliest form of brain cancer [97, 98]. Another therapeutic vaccine PD01A, designed to
target the alpha-synuclein tangles, an aggregated protein associated with pathological cell
death in PD, has entered phase I trials [99, 100]. Extensive studies have shown potential of
passive and active immunization for the treatment of AD [92, 93]. However, peptide or
protein vaccines usually target the peripheral immune system rather than the brain.
Therefore, successes in these vaccines development depend on different set of factors than
those defining successes of CNS therapeutics. Hence we will not refer to vaccines in the
context of our further consideration.
4. Delivery routes for protein therapeutics
The path of a therapeutic agent to its target organ and tissue begins at the site where the
molecule is given to the body. Most current protein therapeutics including FDA approved
products (e.g., antibodies and hormones) are administered by parenteral injection into fat
tissue (subcutaneous, (s.c.)), muscles (intramuscular, (i.m.)) or veins (intravenous, (i.v.)). In
few cases enteral and pulmonary routes were also explored to deliver protein therapeutics
that require frequent dosing to attain the therapeutic window [101–103]. For example, oral
delivery, one of the most convenient and least expensive enteral administration routes is
used for non-CNS targeted therapeutic polypeptides such as insulin, calcitonin, interferons
and human growth hormone [104]. Thee oral bioavailability of polypeptides can be further
increased by their encapsulation into liposomes or nanoparticles or/and using permeation
enhancers [105–108]. However, the oral route is nearly impossible for CNS therapeutics,
because of the presence of two formidable barriers - the gastrointestinal lumen and BBB.
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Early approaches to delivery of protein therapeutics to CNS mainly focused on traditional
parenteral injection routes - i.v., i.m. and s.c. In addition, there is a long history of using the
central administration routes, i.c.v. and intraparenchymal, that bypass the BBB to deliver
proteins to CNS, in particular, during life-threatening conditions (Figure 2). More recently, a
non-invasive administration at the nasal cavity has attracted considerable attention and
shown promise in delivery of therapeutics to the brain. Another way to bypass the BBB
during delivery of therapeutics is to use i.t. route, an approach that has attracted attention in
treatment of CNS disorders because of its relatively low invasiveness compared to the
central administration. A comprehensive description and consideration of the administration
routes is beyond the scope of the current review. However, it is useful to describe some
general principles of these routes to determine potential opportunities and challenges for
delivery of protein therapeutics to the CNS.
4.1 Parenteral administration
The substance delivered by traditional parenteral injection (i.v., i.m., or s.c.) can directly
access systemic veins by bypassing the portal veins and hepatic first-pass elimination and
ultimately be distributed to the whole body including the brain through the vascular system.
A unique advantage of the systemic vascular route is the presence of the dense network of
brain capillaries. These capillaries theoretically can allow for an instantaneous and even
distribution of a therapeutic agent to the closest surrounding cells of the brain, which could
be of great benefit for the treatment of CNS disorders that display widespread pathology or
have unknown location in the brain. Evidently, an effective treatment using parenteral route
relies on the ability to deliver effective amount of a therapeutic agent from the blood to the
brain disease sites. This is often challenged by poor serum bioavailability of a therapeutic
agent (rapid serum clearance, binding to serum proteins, degradation, and tissue distribution)
and the existence of the BBB. Finally, the bioavailability of a therapeutic agent in the brain
interstitial fluid is affected by the clearance of this agent from the cerebrospinal fluid (CSF)
and degradation of this agent in extracellular space (ECS). All these factors collectively
contribute to the actual concentration of therapeutics within the brain and a delivery system
needs to be designed to maximize the efficiency at each step.
Notably, certain macromolecules that can circulate long in the blood and remain stable in
circulation were detected in the brain in spite of their poor penetration at the BBB. For
example, albumin, a BBB impermeable molecule, was detected in CSF at CSF/serum ratio
of 0.5% [109]. The antibodies against amyloid β (Aβ) protein and erythropoietin both having
long half-life in the blood, were shown to reach the brain at sufficient amounts to be
effective in brain disease models [110–114]. The entry of these molecules to the brain is
believed to be associated with an extracellular pathway due to the functional leakiness of
the BBB, which could occur at a number of sites within the CNS, including the
circumventricular organs, the arachnoid space/pial surface and the nasal epithelium [115,
116]. This extracellular pathway at BBB can be described by a nonsaturable and dose-
dependent uptake mechanism at least in the case of IgG [117]. Protein therapeutics
candidates may enter the brain using similar mechanisms. The good candidates for this route
are the molecules characterized by a small volume of distribution, high potency in the CNS,
and absence of brain-to-blood efflux that could efficiently decrease their brain
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concentration. For example, an i.v. infusion of a high dose of recombinant human β-
glucuronidase over long duration resulted in a brain uptake of this protein accompanied by
reduction in toxic substrate storage in central neuronal lysosomes in a
mucopolysaccharidosis VII mouse model [118]. Various methods were developed to
increase serum bioavailability of proteins, such as their conjugation with hydrophilic
polymers like PEG (PEGylation), or encapsulation of in micro- and nano-size particles [2,
119]. From a delivery viewpoint, these methods can increase the blood circulation time and
serum stability of the delivered proteins. Accordingly, they could be benefit CNS delivery of
proteins provided that the delivered materials 1) can still exploit the extracellular pathways,
and 2) remain active in the CNS (or in the case of the nanocarriers are released into the
brain). The key issue, however, is that diffusion of serum macromolecules to the brain via
extracellular pathways is severely limited. Even in most pathological conditions that may be
associated with some leakiness and/or “opening” of the BBB these pathways are not
sufficient to secure a robust pharmacodynamic response. Therefore, in most cases,
increasing transcellular permeability at the BBB is critical to overall improvement of the
parenteral delivery and efficacy of a biotherapeutic agent in the CNS.
Relatively little attention was devoted to improving the bioavailability of therapeutic agents
in the brain. It is probably true that the molecules with increased serum bioavailability
would also be better preserved in brain interstitium and ECS. However, it is not clear
whether a delivery system that improves peripheral bioavailability of therapeutics also
remains intact after crossing the BBB. Justin Hanes’s laboratory has recently reported that
densely coated PEG nanoparticles over 100 nm can diffuse in brain parenchyma ECS [120].
This suggests at least a theoretical possibility of designing a nanoscale size delivery system
that after crossing the BBB can continue its journey through ECS to the target cell within the
brain.
4.2 Inctracerebroventricular infusion
The administration of proteins through i.c.v infusion allows these proteins to bypass the
BBB, directly enter the lateral ventricles and circulate within the ventricular and
extraventricular CSF. However, the clinical trials of i.c.v protein therapeutics have been
rather disappointing. For example, in one trial the NGF was given i.c.v. to 3 AD patients
[62]. Three months after this treatment a significant increase in nicotine binding in several
brain areas in the first 2 patients and in the hippocampus in the third patient were observed.
However, a clear cognitive amelioration could not be demonstrated. Moreover, the treatment
resulted in significant adverse effects such as back pain and body weight loss, which
strongly diminished enthusiasm about the potential of this treatment [62, 121]. In another
clinical trial the GDNF was administered i.c.v. to PD patients [88]. This treatment did not
result in any positive response, although no significant side effects were observed either.
Subsequent trials of GDNF in PD patients also produced contradictory results. For example,
a multicenter, randomized, double blind, placebo-controlled study on 16 subjects concluded
that GDNF administered by i.c.v. injection was biologically active as evidenced by the
spectrum of adverse effects encountered in this study [63]. However, GDNF did not improve
parkinsonism, possibly because the protein did not reach the target tissue - substantia nigra
pars compacta. Likewise, a clinical trial of i.c.v enzyme replacement therapy for central
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lysosome storage disease in Tay-Sachs patients also failed [58]. No improvement was
observed in patients receiving i.c.v. β-hexaminidase, an enzyme that depletes lysosome
storage of GM2 ganglioside [58].
From the delivery standpoint a key challenge for the i.c.v. route is the ependymal lining,
which albeit is less restrictive than the BBB still acts as a significant barrier at the ventricle
surface hindering the diffusion of substances from CSF into brain parenchyma [122].
Indeed, the brain section of animals receiving i.c.v infusion of basic FGF (bFGF) and BDNF
both confirmed that the compounds were distributed only at the ventricle surface with
minimal amounts detected in deep brain parenchyma [123–125]. The limited brain uptake
following i.c.v. administration could be further compounded by a rapid turnover of
therapeutic agents from CSF to systemic circulation, their degradation in ECS, their slow
diffusion within brain interstitial fluid and their sequestration by brain tissues (e.g.
ependymal, pial and glial cells) [125]. Based on the experience with i.c.v. administration of
native forms of proteins one could suggest that incorporating proteins and other therapeutic
molecules in suitable delivery systems is perhaps a necessity for future development of
drugs using this route. An optimal delivery system would need to display permeability at the
ependymal layer, efficient diffusion in brain interstitial fluid and improve bioavailability of
the delivered agent within the CSF.
4.3 Intraparenchymal injection and implantation
Proteins can be directly administered into brain parenchyma via intraparenchymal injection
or implantation. This invasive central route allows bypassing both the BBB and the
ependyma lining barrier at the ventricular surface. However, due to limited diffusion in brain
interstitial fluid biotherapeutic molecules often locally spread in an area not more than about
2 mm from the site of intraparenchymal injection [123, 126]. The majority of injected
substance was then eliminated from the CNS interstitial fluid [127]. For more than a decade,
convection-enhanced delivery (CED) has been used to improve the locoregional
concentration of substances within brain interstitium by stereotactically placing catheters to
deliver a bulk flow upon gradient pressure. The detailed evolution of this technology and the
main issues that need be addressed for its further successful development are reviewed
elsewhere [128–130]. Although initial animal studies showed that CED of transferrin in
brain white matter produced a homogenous penetration in gray matter after 24 hr. infusion
[128], CED of protein therapeutics in clinical trials has not been encouraging in most cases.
CED of recombinant human GDNF failed to confer clinical benefit to a trial involving 34
PD patients [64]. In this trial GDNF (called “liatermin”) was continuously infused directly
in the putamen (ipu). The failure of this trial, as suggested by studies of CED of GDNF in
primates, might have been related to the extremely high concentration of GDNF around the
catheter tip and limited diffusion into surrounding brain parenchyma which resulted in a
very limited drug bioavailability [65, 131]. The inconsistent results of clinical studies had
decreased enthusiasm about using GNDF for PD treatment with no new trials being reported
for several years. However, recently British scientists developed a brain implant device that
allows GDNF be given more reliably in the putamen area of the brain. Recruitment for the
clinical trial in PD patients using this delivery strategy for GDNF is currently open
(UKCRN ID 12085). An early clinical trial involving CED of antibody against EGFR to
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malignant glioblastoma patients was not completed because of severe inflammatory reaction
prior to tumor debulking [132]. Interestingly, CED of enzyme replacement therapy showed
some consistency between preclinical study and clinical trial and appeared to be more
successful. Thus CED of glucocerebrosidase to rat and primate brains showed wide enzyme
distribution in various brain regions [133]. The CED of this enzyme to neuronopathic
Gaucher’s patient followed by i.v. enzyme therapy prevented the deterioration in seizures
and cranial nerve deficits while showing no clinical signs of toxicity [133]. The variations in
the outcomes of CED clinical trials seem to suggest that the slow diffusion still might be a
barrier for certain molecules. Moreover, one should carefully examine the surgery or drug
associated toxicity arising from this invasive regimen. Nevertheless, radiolabeled
antibody 124I-8H9 is currently undergoing clinical trials for treatment of brain cancers using
CED [68, 69]. This is the first time that CED of therapeutic protein targets into the tumor of
brain stem aiming to treat patients with diffuse intrinsic pontine glioma. In parallel, there has
been a major effort in developing polymer-based nanoparticles and matrices (e.g. liposome,
dendrimer, polystyrene nanospheres, maghemite nanoparticles and other lipid nanoparticles)
that can be used as implants to produce a sustained release of a substance in localized areas
within the brain interstitium [134]. Most of these studies, however, focus on development of
small molecule drugs in preclinical or clinical study for treatment or diagnosis of brain
tumors.
4.4 Intranasal administration
Different from traditional nasal spray that is administered in the vicinity of the turbinates
and thus distributes through the systemic circulation, administration at the level of nasal
cribriform plate allows substances to bypass the BBB and directly enter the brain with
minimum serum exposure. This administration procedure, known as intranasal-to-brain
(INB), is more patient friendly compared to other approaches and importantly allows to
avoid the BBB, serum clearance and peripheral metabolism. The INB administered proteins
have reduced systemic side effects and display rapid central action onset. The olfactory
nerve originates in the olfactory mucosa in the anterosuperior nasal cavity and then travels
down the olfactory tract until it reaches the olfactory bulb, where the fascicles of the
olfactory nerve pass through the cribriform plate, a perforated bone in the base of the skull,
into the highest reaches of the nasal cavity. Three known pathways conduct substances
across the cribriform plate into the CNS [135]: i) diffusion through the CSF and brain
interstitial fluid; ii) retrograde transmission via the olfactory nerves to the olfactory bulb;
and iii) retrograde transmission via the trigeminal nerve to the trigeminal nuclei. Growing
preclinical evidence suggests that various protein molecules including neurotrophic factors,
hormones, antibody fragments, and peptides can reach the brain via INB route in adequate
amounts to be effective in the animal models [136–139]. Moreover, several intranasal
therapeutics tested in clinical trials (e.g., cholecystokinin [140], corticotrophin-releasing
hormone [141] and insulin [142]) elicited measurable central responses. For example, nasal
insulin has profoundly improved memory in AD patients [56]. Small peptides, such as
antidiuretic hormone arginine-vasopressin (1.1 kDa) and neurohypophysial hormone
oxytocin (1 kDa) have shown significant promise as nasal spray products [143–149].
Further, intranasal arginine-vasopressin was detected in human lumbar CSF and shown to
increase brain electrical response to various stimuli [150, 151].
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At the same time, there are conflicting reports about the advantage of INB route over
traditional routes (i.v., s.c. and i.m.) in efficiency of delivering polypeptides to the brain.
Clinical trial of intranasal peptide YY3–36 (PYY) dosed at 600 µg for 12 weeks failed to
induce weight loss in obese patients and furthermore, significant nausea and vomiting were
observed in some cases [57]. In animal studies comparable and low levels of brain
accumulation were reported after INB and i.v. administration of an agonist of the glucagon-
like peptide 1 (GLP-1) receptor, exendin-4 [152]. Therefore, to attain brain concentrations
within the therapeutic window, multiple i.n. dosing of therapeutic peptides is required. For
example, daily intranasal administration over 10 days of a 16-kDa adipose-derived hormone,
leptin reduced the body weight of diet-induced obese mice [153]. It should be also noted that
the brain region distribution patterns after i.n. administration vary from substance to
substance, suggesting that there might be different mechanisms and pathways involved in
the delivery of these substances. In some cases, the INB administered drug is taken up in a
brain region irrelevant to the biological target of this drug. For example, interferon β-1b after
intranasal administration in rats accumulated in both in CNS as well cervical lymph nodes
[154]. Accordingly, there is a need to focus on brain regional distribution of INB-
administered therapeutic agents and analyzing their pharmacodynamic responses. In some
cases, there might be a possibility to control the brain regional distribution of peptides after
their INB delivery. For example, pituitary adenylate cyclase activating polypeptide
(PACAP) after i.n. administration in mice exhibited the highest uptake in the striatum and
occipital cortex, but combining this polypeptide with β-cyclodextrin increased its uptake in
hypothalamus by 8-fold and hippocampus by 2-fold [155].
The unique factors hindering the brain bioavailability of substances administered via the
INB route are likely to include the presence of the nasal epithelium barrier, fast clearance of
solutes in CSF, and limited penetration at the neuronal pathways. Overcoming the barriers
behind nasal epithelium and targeting the delivery-relevant brain regions is of great
importance for developing nasal protein therapeutics. Currently most therapeutic agents
administered via INB route are formulated with excipients that act either as permeation
enhancers at the olfactory epithelium or mucoadhesives to extend residence time in the nasal
cavity. In some cases, vasoconstrictors are also co-administrated to limit the absorption of
the therapeutics by non-olfactory epithelium into the systemic circulation. However, the use
of drug delivery systems to improve CNS delivery of proteins after INB administration is
relatively poorly explored. Nevertheless, some studies have shown that delivery systems
could play significant role in this route. For example, the intranasal delivery of albumin to
brain was shown to increase after albumin encapsulation in liposomes [156]. Another
example is HRP, a hydrophilic and BBB impermeable enzyme, that most likely crosses the
cribriform plate by leaking through the intercellular space of nasal epithelium and then
distributes within the brain by diffusion through CSF [116]. Modification of HRP by wheat
germ agglutinin has increased the HRP adsorptive endocytosis at both nasal epithelium and
olfactory neurons and therefore the trafficking of modified HRP to brain regions is likely to
involve the olfactory and trigeminal nerve pathways [157, 158]. Our unpublished data also
showed that modification of leptin with amphiphilic block copolymers increased overall
brain uptake of intranasal leptin and importantly improved leptin targeting to hypothalamus,
the site where leptin controls appetite. Overall, there is a potential of improving CNS
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delivery of INB administered protein therapeutics by using drug delivery strategies
including these discussed below. The unmet need to treat CNS related disorders hopefully
will push forward the studies in this direction.
4.5 Intrathecal administration
Therapeutic agents can be injected into the subarachnoid space of the spinal cord allowing
them to bypass the BBB and access the brain. This approach known as i.t. administration
goes back to the pioneering work of J. Corning who injected cocaine in the lower lumbar
vertebrae for the purpose of local spinal anesthesia [159]. Subsequently, it was established
as a clinical procedure for administration of drugs with main indications for anesthesia and
pain management. Its least invasive and clinically feasible modes include 1) injecting a
substance at the lumbar region through lumbar puncture to evoke an acute postoperative
response or 2) using a slow infusion device for maintenance of a sustained effect required
for chronic management. I.t. administration of protein therapeutics for treatment of CNS
related disorders was also explored both in pre-clinical studies and clinical studies. For
instance, an antibody against Fas ligand was administered i.t. to treat the acute phase of
multiple sclerosis in a mouse model of experimental autoimmune encephalomyelitis (EAE).
Notably, this antibody was more potent in blocking Fas-mediated tissue injury and
suppressing EAE progression after i.t. administration (20 µg/day for 3 days) than when it
was given i.p. (200 µg/day for 3 days) [160]. Another study, however, reported a negligible
effect of i.t. infusion of NGF (125 ng/h for 7 days) in a rat model of neuropathic pain [161].
According to a more recent report a 20 kDa glycoprotein, sonic hedgehog (Shh) exhibited
neuroprotective effect after i.t. administration in a rat model of ischemic stroke at a dose of
150 µg [162]. More recently, using position emission tomography (PET) five more proteins
were shown to rapidly distribute to brain parenchyma after i.t. administration in animal
models [61, 163]. Clinical studies reported include BDNF given i.t. to amyotrophic lateral
sclerosis patients at five different dose levels starting from 25 µg/day for 12 weeks [164].
Although no efficacy was proven in this study, a notable amount of BDNF was detected in
the CSF of patients between day 11 and week 24 of treatment even at the lowest dose
applied [164].
As of today, perhaps the most successful example of i.t. application of protein therapeutics
for CNS related disorders involves ERT for lysosome storage diseases [61, 165–168]. For
example, α-L-iduronidase (rhIDU), an enzyme deficient in mucopolysaccharidosis I (MPS
I) was i.t. administered in MPS I model in dogs [168]. The deep penetration of the enzyme
into brain regions was shown. Moreover, four weekly i.t. doses of ~1 mg rhIDU produced
profound amelioration of the MPS I symptoms. Another study further supported the use of
i.t. route over i.c.v. or i.v. routes using I2S, an enzyme deficient in MPS II lysosome storage
disease [61]. Intralumbar injection of I2S in monkeys produced nearly same levels of the
enzyme in the brain gray matter 4 hr. after treatment as did the i.c.v. injection and over 100-
time higher levels than those observed after i.v. administration of this enzyme [61].
Moreover, i.t. I2S treatment has effectively reversed the brain pathology after 3 injections at
a dose of 250 µg in a mouse model of MPS II [61]. These efforts have provided momentum
towards the clinical use of i.t. I2S in the treatment of MPS II disorder [60].
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The physiology and mechanisms underlying the i.t. delivery of macromolecules to the CNS
have been discussed elsewhere [169]. Briefly, the transport of solutes from the site of i.t.
injection to the brain parenchyma includes 1) initial spread and diffusion in the CSF that is
likely driven by pulsatile remixing; 2) clearance through drainage of the CSF; 3) active and
pulsation-assisted translocation of remaining substance into the perivascular space; and 4)
transfer to brain parenchyma. The latter may involve various mechanisms including
penetration at the glia limitans and pial cells, convective transport (“bulk flow”), and
anterograde axonal transport. Current data suggest that the location and volume of the
administered bolus are the most important factors in the initial spread of therapeutic
substance in the CSF after i.t. administration. The subsequent processes, however, are less
understood. Although very little is known about immunogenicity of i.t. proteins, one study
reported a dose-dependent immune response and a meningeal lymphocytic infiltrate in the
dogs that received i.t. administration of rhIDU [168].
Little work was done using drug delivery systems to improve the outcomes of the i.t.
administration of therapeutic agents. However, one can expect that nanomedicine strategies
can address some common problems of protein therapeutics delivery using this route, such
as poor stability of proteins in the CSF and perivascular space, limited permeability of
proteins from the perivascular space into the brain and protein immunogenicity. For
example, PEGylation of IL-10 increased the CSF concentration of this protein as well as the
level and duration of the therapeutic response after i.t. administration of this protein in an
animal model of neuropathic pain [170]. Additionally, a use of delivery systems might be
worth exploring to improve permeation of i.t. administered proteins.
Overall, the choice of the administration routes for the CNS therapeutics is most challenging
due to the restricted anatomical access to the CNS, and the complicated CNS environment.
There is no doubt that this choice must account for the efficacy, safety, disease stage
(chronic and acute) and patient concerns (convenience and cost). Therefore, during
development of new CNS therapeutics, in particular, protein therapeutics, selecting the
optimal administration route and the delivery strategy specific for this route is essential and
accounts for the success, perhaps, no less than identifying the proper therapeutic target.
5. Chemical modification of proteins for CNS delivery
To date some of the most extensive studies to increase protein permeability at the BBB have
involved protein chemical modification with various strategies such as a) cationization, b)
fusion with cell-penetrating peptides (CPPs), c) fatty acid acylation, d) conjugation with
brain targeting ligands, and e) modification with polymers (Figure 3). Notably, the protein
modification points, linkers, modification degree and the conjugation chemistry are all
important design considerations having a dramatic impact on the properties of resulting
conjugates and their in vivo performance. Generally, lysine residues of a protein serve as
common modification points. Other site-specific chemistries involve protein N- and C-
terminus modifications and disulfide bridge insertion [171–180]. Modification of a protein
with CPPs and brain targeting ligands can be also accomplished by genetic engineering. The
linker in such fusion proteins need be designed in such a way that it allows the independent
folding of each protein and also enables release of the two separate proteins if needed.
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However, detailed consideration of these design factors is outside of the scope of this
review. Below we present the different chemical modification strategies and assess their
state of development and promise for future pharmaceutical use. The representative
examples of these strategies and some principal observations are presented in Table 2.
5.1 Cationization
A simplest way to cationize a protein is to chemically modify its carboxylic acid groups with
synthetic (e.g. hexamethylenediamine) or natural amines (e.g. putrescine, spermidine and
spermine). In an early study Pardridge and co-workers modified native albumin (pI 4) with
hexamethylenediamine and produced a cationized albumin (pI > 8). They demonstrated that
β-endorphin, a BBB impermeable peptide, after conjugation with such cationized albumin
was rapidly taken up by isolated brain capillaries in vitro in a temperature dependent
manner. Moreover, the autoradiography data showed that the conjugate crossed the
capillaries and distributed in the brain parenchyma following intracarotid injection in rats
[181, 182]. An increase in the brain uptake was also observed for cationized IgG (an
increase in pI from 5–6 to >10) in both in vitro and in vivo [183]. Both studies reported that
the uptake of cationized proteins in the brain was saturable. Even though the assessment of
BBB function was not a part of this study, authors claimed that the increase in brain uptake
was not related to the breakdown of the BBB [183]. Subsequently, Poduslo and colleagues
demonstrated ability of several cationized proteins (e.g. superoxide dismutase (SOD),
insulin, albumin, IgG and neurotrophic factors) to cross the BBB without disrupting its
integrity [184, 185]. In these studies the permeability of the cationized proteins at the BBB
after i.v. administration was assessed by calculating the permeability coefficient times
surface area (PS), a reliable PK measure of brain entry. Moreover, the lack of the BBB
leakiness was unequivocally proven by little or no change in the volume distribution of a
native protein co-injected with the cationized protein [184, 185].
Some therapeutic or disease relevant effects of cationized proteins in animal models were
also reported. For example, systemic administration of a putrescine-modified SOD resulted
in neuroprotective effects in rats with global cerebral ischemia [186]. The diamine- and
gadolinium-derivative of human Aβ peptide was shown to have enhanced in vitro binding to
AD amyloid plaques and increased in vivo permeability at the BBB of normal adult mice.
Specific targeting of the modified Aβ peptide to amyloid plaques in the brain was also
demonstrated in a transgenic mouse model of AD [187].
It was suggested that cationization increases permeability at the BBB by promoting
interaction and transcytosis of the protein across the BMECs. However, the exact
mechanisms remained unclear since permeability did not directly correlate with the number
of positive charges of the polyamines in the cationized protein [184, 188]. Along with an
increased BBB permeability cationization also resulted in undesirable consequences such as
an increase in the serum clearance of the protein. For example, when was modified by
polyamine, its plasma half-life time dramatically decreased from 3 min to about 0.6 min
[184]. Similar effects were observed for cationized IgG, albumin and insulin [184]. The
decreased half-life could offset improved BBB permeability of the cationized proteins and
decrease their net brain accumulation especially for proteins having intrinsically rapid blood
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clearance. Moreover, despite that cationization was not reported to disrupt BBB in these
studies, concerns about dose-limited toxicity of cationic substances persist. In particular,
although low doses of cationized IgG used in PK studies ware safe for peripheral organs and
brain capillaries [183], considerable toxicities (immune complex formation, membranous
nephropathy) were observed after injecting therapeutically relevant doses to rabbits [189,
190]. Likewise, administration of high dose of protamine alone also resulted in an increased
cerebral and peripheral vascular permeability [191–194]. Thus potential toxicity of
cationized proteins and the resulting limitations to the therapeutic window of possible
therapeutic agents are the main factors that have limited the development of this technology
for the clinical use.
5.2 Protein fusion with CPPs
Modification with CPPs is yet another approach to improve brain delivery. Examples of
CPPs derived from natural proteins are trans-activating transcriptional activator (TAT),
penetratin, and the Syn-B vectors. Other CPPs homoarginine vectors, the model amphipathic
peptide, transportan and chimeric peptides (sequence signal-based peptide and fusion
sequence-based peptide) are engineered artificially. Heterogeneous in size (10–27 amino
acids) and sequence, all CPPs are comprised of basic amino acids and are cationic.
Translocation of CPPs through cell membrane may occur by passive diffusion.
Alternatively, CPPs can destabilize the phospholipid bilayer and form inverted micelles that
enable entry of CPP and its attachment, e.g. proteins into cells without leaving an aqueous
environment [195–198]. More detailed description of the CPP internalization mechanisms,
and other properties such as stability, toxicity and immunogenicity were reviewed elsewhere
[199]. Here we focus on use of CPPs for delivery of proteins to CNS.
Schwarze and colleagues published a seminal work demonstrating ability of CPP to deliver
proteins across BBB [200]. In their study the NH2-terminal TAT (47–57)-galactosidase
fusion protein (120 kDa) injected i.p. in mice was detected by immunochemical staining
initially at 2 hr in brain microvessels and then at 4–8 hr in brain parenchyma. No PK studies
were performed. Nevertheless galactosidase activity was visualized in sagittal and coronal
brain sections as well as in liver, kidney, lung and heart (myocardium) and spleen. TAT did
not appear to disrupt BBB as the Evan’s blue albumin complexes co-injected with TAT
were excluded from the brain tissues. Subsequently, TAT peptide was fused with GDNF and
injected i.p. in a mouse model of PD. The fusion protein crossed the BBB and reached
substantia nigra as was shown by immunohistochemical staining. However, the treatment
did not prevent the loss of dopaminergic neurons in PD mice, possibly because the amount
of the fusion protein delivered to the target site was not sufficient [201]. A TAT-based
system was also used to deliver Bcl-xL protein, a well-characterized death-suppression
molecule, to the CNS for treatment of stroke. Intraperitoneal injection of TAT and Bcl-xL
fusion protein resulted in a robust protein transduction in neurons, and a dose-dependent
decrease of cerebral infarction in a mouse middle cerebral artery occlusion (MCAO) model
of ischemic stroke [202]. Similarly, a reduced infarct volume and neurological deficits were
observed after i.v. injection of TAT-Bcl-xL fusion protein 1 hr. before or immediately after
the ischemia induced in a rat MCAO model [203]. A recent study reported that TAT-leptin
fusion protein was i.v. injected to mice fed with high-fat diet. Immunohistochemical staining
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suggested increase in leptin accumulation in hypothalamus in the TAT-leptin treated mice,
compared to the unmodified leptin or saline-treated animals. Importantly, TAT-leptin also
prevented body-weight gain more efficiently compared to leptin [204]. Cai et al. recently
described positive effects of TAT-mediated delivery of neuroglobin (Ngb) on focal cerebral
ischemia outcome in mice [205]. After i.v. injection the TAT-Ngb fusion protein was
detected in mice brain tissues by immunohistochemistry and western blotting. The group
treated with TAT-Ngb 2 hr. before MCAO showed smaller brain infarct volume and
improved neurologic outcomes compared to the control groups. Moreover, the group treated
with TAT-Ngb after MCAO and reperfusion showed significantly increased neuronal
survival in the striatum, compared to the controls [205].
Besides TAT some other CPPs, such as Syn-B vectors and Rabies virus glycoprote-
inderived peptide (RDP), were also shown to deliver small molecules and proteins across
BBB [206, 207]. For example, Xiang et al reported efficient hippocampus targeting by a β -
galactosidase-RDP fusion protein [206]. Interestingly, a simple mixing of a protein with
CPP also improved delivery of multiple proteins such as β-galactosidase, human IgG and
IgM to mouse brain [208].
However, CPP have displayed various toxicities including neurotoxicity, endothelial cell
apoptosis and inflammation [199], which decreased likelihood of their translation to clinic
use. Another obstacle to future product development is a non-specific penetration of CPP-
modified proteins into peripheral tissues. Thus a case-by-case preclinical toxicology study
accounting for stability, efficacy and safety must be performed to evaluate further
possibilities of using this technology for specific CNS therapeutic application.
5.3 Fatty acid acylation
Early work by Chekhonin and Kabanov described protein modification with fatty acids for
brain delivery [209]. For example, a neuroleptic drug (trifluoperazine) was attached to Fab-
fragments of antibodies against gliofibrillar acid protein (GFAP) or brain specific α2-
glycoprotein (α2-GP). The drug-Fab conjugates were then modified with stearate in reverse
micelle system formed by a surfactant, sodium bis-(2-ethylhexyl)sulfosucciate (Aerosol OT)
in octane. Stearoylated Fab fragments of brain-specific antibody exhibited brain
accumulation and a drastic increase in neuroleptic activity of trifluoperazine following
intracoratid injection into rats. In contrast, fatty acylated Fab fragments of nonspecific
antibodies accumulated in the liver rather in the brain [209]. Subsequent studies using
BMECs as an in vitro BBB model demonstrated that stearoylation of ribonuclease A
increased the transport of this enzyme across the BBB by almost 9-fold [210]. In another
study Slepnev and colleagues used a membrane-impermeable enzyme, HRP as a model
protein to examine effects of stearoylation of the protein on its interaction with cells [211].
This work demonstrated that stearoylation increased binding and internalization of HRP in
mammalian cells, albeit the internalized protein accumulated in endocytic vesicles but not in
the cytoplasm [211]. Notably, the stearoylated HRP displayed much greater binding with a
hepatic cell line than with epithelial cells, which could be due to the presence of the fatty
acid binding receptor in hepatocytes. Subsequent PK study from Kabanov and Banks’
laboratory demonstrated that after i.v. injection stearoylated HRP was able to cross mouse
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BBB at a higher influx rate than the native HRP [212]. This work also reported about 13%
increases in brain uptake of stearoylated HRP over 200 min as compared to native HRP. The
volume of distribution of fatty acylated HRP also increased due to its non-specific
distribution in liver and other organs [212]. Shen and colleagues reported that palmitoyl
residue conjugation through a disulfide linker to interferon α enhanced its circulation and
liver accumulation; the effect of palmitoylation on brain uptake of interferon α was not
reported [213].
Overall fatty acylation is likely to result in the increased binding of proteins to brain
microvessel endothelial cell membranes through hydrophobic interactions of the attached
lipid anchor with the membrane bilayer [212]. In addition many other factors can contribute
to delivery of proteins following lipidization. Cellular binding might be further increased
when the modified protein itself contains a polybasic motif which in addition to lipid carrier
serves an anchor for interaction with cell membrane [214]. A transporter-mediated
mechanism might come in play when proteins are modified with essential fatty acids, such
as linoleic acid, which is naturally transferred to the brain by transporters [215, 216]. Other
factors including plasma protein binding, intracellular sequestration, non-target organ uptake
can contribute to plasma PK and biodistribution and should be taken into account when
developing CNS targeted therapeutics using this approach.
As of today perhaps the most advanced application of fatty acylated proteins is the
development of long-acting anti-obese hormones that originate from the gut-intestine tissue
and act partially or exclusively within the CNS to control appetite and energy consumption.
Interestingly, fatty acylation of gut-brain hormones is a naturally occurring phenomenon. In
fact, the octanoic acid acylated ghrelin acts as an important cognate ligand to stimulate
growth hormone release and regulate energy hemostasis [217]. Post-translational O-n-
octanoylation of ghrelin at the serine 3 position is indispensible to the hormone binding to
and activation of the growth-hormone secretagogue receptor [218, 219]. The brain PK study
did show that octanoylation of ghrelin has a dramatic effect on its transport characteristics
across the BBB [220]. Another example is liraglutide, a GLP-1 analog modified with a C16
fatty acid chain that is currently being tested in Phase III clinical trial as an anti-obesity drug
[221–224]. This modified peptide analog displays notable improvement in its PK profile
(longer circulation, smaller volume of distribution), and can be used once a day to replace
exenatide (a native form of GLP-1) given twice daily. Interestingly, GLP-1 as well as many
other gut-brain hormones control appetite and thermogenesis at two sites: peripherally by
signaling the vagus nerve surrounding gut-intestine and centrally acting at the receptor in the
brain. However, in spite of improvement in the hormone’s peripheral circulation, no brain
PK data were reported to support the role of fatty acylation to increase GLP-1 brain uptake.
Further discussion of the application of the fatty acylation for development of gut-brain
hormone therapeutics can be found elsewhere [225].
5.4 Conjugation with brain-targeting ligands
To maintain homeostatic environment of CNS brain endothelial cells express a variety of
receptors and transporters that mediate blood-to-brain transcytosis of hormones, transport
proteins and other essential substances including insulin, growth factors, low-density
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lipoprotein (LDL), amino acids, and glucose. Low molecular mass drugs or polypeptides can
be designed to closely resemble endogenous ligands of these receptors. Conjugation of such
artificial ligands to polypeptides (as well as other biomacromolecules) can improve delivery
of these molecules to the brain [226–228]. Such brain delivery strategy is frequently referred
to as “Trojan horse”. This strategy has a few well-known caveats. First, the ligand-modified
molecules compete with the endogenous ligands, which can potentially lead to 1) ineffective
brain targeting; or 2) side effects induced by endogenous ligand deficiency in the brain.
Second, chemical conjugation can affect binding affinity of the ligand to its receptor and/or
the biological activity of molecule to be delivered. The linkers used for conjugation can
significantly alter the PK profile of the conjugate and affect the release and stability of
delivered molecules. Below we consider several such Trojan horse approaches using various
targeting ligands such as antibodies against transferrin receptor (Ab-TfR), antibodies against
insulin receptor (Ab-InsR), ligands of LDL receptor-related proteins 1 and 2 (LRP1 and
LRP2), melanotransferrin (MTf), receptor associated protein (RAP) and angiopep.
Ab-TfR—TfR is responsible for iron transport to the brain. Both transferrin and Ab-TfR
bind with TfR in brain endothelium albeit they use different binding sites. However,
transferrin is not a good candidate for the Trojan horse strategy because its TfR binding site
is already saturated by endogenous transferrin. Pardridge and colleagues reported that Ab-
TfR (OX26), a mouse IgG2a monoclonal antibody against rat TfR accumulated in the brain
to a greater extent than in liver or other organs [229] and can serve as vehicle for delivery of
various proteins to the brain [230]. Thus, basic bFGF conjugated to OX26 through biotin-
streptavidin reaction accumulated in rat brain at 0.05% injected dose/g brain tissue, which
was 5-fold higher than non-conjugated bFGF [231]. A single i.v. injection of a bFGF-OX26
conjugate produced nearly 80% reduction in infarct volume in a rat model of transient
ischemic stroke [232]. In another study conjugation of OX26 to EGF resulted in increased
the brain uptake and accumulation of EGF in brain tumors after i.v. administration [233].
Other proteins such as vasoactive intestinal peptide (VIP), BDNF as well as nucleic acids
were also conjugated with OX26 for brain delivery [234, 235]. An alternative to OX26, a
chimeric monoclonal antibody against mouse TfR (CTfRMAb) was also used in production
of fusion proteins for brain delivery of erythropoietin (EPO), α-L-iduronidase (IDUA), anti-
Aβ amyloid antibody, Aβ1–40 peptide, GDNF, tumor necrosis factor decoy receptor (TNFR)
and others [236–246]. Therapeutic effects of the fusion proteins in relevant CNS disease
models were also demonstrated. For example, Boado et al. reported that IDUA-CTfRMAb
fusion protein reduced brain intracellular lysosomal inclusion bodies in a mouse model of
MPS I [239]. Studies were also reported using antibody against human TfR. These
antibodies may have greater potential for clinical translation than OX26 and CTfRMAb,
which are specific to mouse and rat, respectively. For example, Xu et al. used scFv fragment
of antibody against human TfR to target cationic immunolipoplex to breast tumor [247].
Another study demonstrated brain accumulation of the scFv fragment against human TfR in
mice [248].
The transcellular permeability at the BBB is governed by the internalization of the
molecules at the luminal side of the brain endothelium, the intracellular sorting of the
molecules in the endothelial cells and the release of these molecules from the abluminal side
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of the endothelium. In spite of the aforementioned reports showing that Ab-TfR improved
the brain delivery of various cargo the use of this strategy for the delivery proteins across the
BBB to brain parenchyma was a matter of discussion for over a decade. In early days Moos
and Gosk have shown that most of brain-associated OX26 accumulated in brain capillary
endothelium and not in brain parenchyma [249, 250]. It was not until recently when
thorough studies by scientists from Genentech, Inc have provided an insightful
understanding of this issue [117, 251, 252]. They confirmed by microautoradiography and
confocal microscopy that the majority of i.v. Ab-TfR was indeed entrapped in the brain
endothelium due to lysosomal sorting. To improve BBB penetration a lower affinity
antibody was developed and evidenced by less degradation within the brain endothelium and
maintains the capability to bind with TfR and internalize at the brain endothelial luminal
side but also is easily released at the abluminal side of the BBB. They showed that at
therapeutically relevant concentrations in mouse, this lower affinity antibody was released
from the BBB and broadly distributed in brain parenchyma. The brain delivery of this low
affinity Ab-TfR was then significantly improved after i.v. administration [117]. This
example underscores the importance of in-depth understanding of intracellular trafficking
(e.g. lysosome escape, early endosome targeting) and sorting of the delivered materials
within the brain endothelium, a field that has been insufficiently explored.
There is also a possibility to avoid covalent conjugation of Ab-TfR and the transported
molecules, which can facilitate pharmaceutical development of the respective delivery
systems. Taking advantage of the inherent Y-shape structure of antibodies, Genentech
scientists also made substantial progress by engineering a bi-specific antibody with one Fab
fragment (arm) derived from low affinity Ab-TfR and another Fab fragment (arm)
containing an antibody against β-secretase (Ab-BACE1) [117, 252]. Without additional
changes in its molecular weight, size and overall structure, this bi-specific antibody
embedded therapeutic function of Ab-BACE1 for the treatment of AD and transcytosis
capability at the BBB arising from the low affinity Ab-TfR. Indeed, the bi-specific antibody
accumulated in the brain in a greater amount than Ab-BACE1 and significantly reduced the
brain Aβ levels in a mouse model of AD [117, 252]. Unfortunately, targeting the transferrin
receptor at the BBB apparently also increases the peripheral exposure of the bi-specific
antibodies, which raises some safety concerns. It was shown that Ab-TfR after i.v. injection
in mice at doses starting from 1 mg/kg caused acute clinical signs and decreased reticulocyte
count [252]. Therefore, prospects of the clinical use of Ab-TfR containing bi-specific
antibodies remain uncertain.
Ab-InsR—A high affinity insulin receptor (InsR) in brain endothelium binds insulin and
enables its transport across the BBB. Insulin cannot be used as a carrier protein in vivo due
to a risk of hyperglycemia. However, Pardridge and colleagues have successfully used Ab-
InsR to deliver proteins to the brain [253]. In particular, a conjugate of GDNF with fully
humanized antibody against human InsR (HInsR) exhibited neuroprotective effect in a rat
model of transient ischemic stroke [254, 255]. This conjugate was also shown to accumulate
in a rhesus monkey brain. The fusion constructs comprising monoclonal antibody against
HInsR with EPO, TNFR and anti-Aβ amyloid ScFv were also evaluated as potential
therapeutic agents [256–259]. However, concerns about possible interference of such
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constructs with insulin receptor and adverse effects on glucose metabolism decrease
enthusiasm about their possible clinical use.
LRP1 and LRP2 Ligand—LRP1 (CD91) and LRP2 (gp330) are type I transmembrane
proteins that belong LDL receptor superfamily. LRP1 and LRP2 both contain intracellular
and transmembrane domain along with an extracellular domain characteristic of LDL
receptor family [260, 261]. Both proteins interact with a wide range of ligands and facilitate
their endocytosis. LRP1 also plays a major role in regulation of signaling pathways. The
dysfunction of LRP1 has been associated with a number of CNS related disorders, including
AD, stroke and multiple sclerosis [262–264]. A large number of ligands are shared between
LRP1 and LRP2, such as lipoprotein lipase, α2-macroglobulin, receptor associated protein
(RAP), lactoferrin, tissue- and urokinase-type plasminogen activator (tPA/uPA), etc.
However, some ligands (e.g. melanotransferrin (or P97), Aβ precursor protein, complement
C3, apolipoprotein E, and HIV-1 Tat protein) exhibit relatively higher specificity to LRP1,
whereas others (e.g., apolipoprotein J, Aβ bound to apolipoprotein J and apolipoprotein E,
very-low-density lipoprotein (VLDL)) are more specific to LRP2 [265–271]. Some of these
ligands, such as angiopep, MTf and RAP, have shown capability for LRP mediated transport
across the BBB and were used for delivery of proteins to the brain.
Angiopep—Angiopep is a family of 19 amino acid sequences derived from aprotinin, a 6.5
kDa pancreatic trypsin inhibitor that by itself is rapidly transported across the BBB through
LRP mediated pathway [272]. One member of this family, angiopep-2, displays the highest
transcytosis rate at the BBB and best accumulation in brain parenchyma among all identified
angiopep peptides [272, 273]. It is now clearly shown that angiopep-2 is transported through
LRP1 mediated pathway [274, 275]. Currently the most successful application of Angiopep
in CNS delivery is ANG1005 (Angichem, Inc), a paclitaxel-angiopep-2 conjugate that
contains three paclitaxel molecules attached to two lysine residues and N-terminus of
angiopep-2. ANG1005 was shown to bypass Pgp and exhibit greater brain uptake than free
paclitaxel in in situ mouse brain perfusion study [276]. ANG1005 has shown some
antitumor effects in intracerebral glioblastoma in mice, although no direct comparison with
paclitaxel was made [276]. Nevertheless the drug was evaluated in the phase I clinical trial
in the patients with recurrent malignant gliomas and brain metastases and was fairly well
tolerated showing a toxicity profile similar to that of Taxol. Importantly, the concentration
of paclitaxel in tumors removed from some ANG1005 treated patients exceeded that
previously reported for patients treated with Taxol [277, 278]. This might suggest that the
drug penetration at the BBB using ANG1005 was improved compared to regular Taxol
chemotherapy. Two other angiopep-2-based conjugates, ANG1007 (angiopep-2-
doxorubicin) and ANG1009 (angiopep-2-dimethylglycine etoposide), also demonstrate
improvement in brain accumulation and brain tumor inhibition in animal studies [279]. The
use of angiopep-2 for the brain delivery of various macromolecular species was also
reported. Examples include polyamidoamine dendrimers-PEG/DNA nanoparticles [280],
PEG-polylactic acid (PLA) polymeric micelles [281], poly(ethyleneimine)-PEG (PEI-PEG)
based polymeric micelles loaded with amphotericin B [282], and a few others [283–286].
Angiochem also reported conjugation of angiopep-2 to anti-HER2 antibody (ANG4043) and
anti-EGFR antibody [287, 288]. In both cases, modification was reported to increase the
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antibody transport rate across BBB as shown using in situ brain perfusion and fluorescent
imaging in a mouse [287, 288]. In another study, angiopep-2 conjugation to a short sequence
analgesic peptide, neurotensin (1.6 kDa) (ANG2002) appeared to be successful in targeting
thins peptide to the brain for the treatment of chronic pain [289]. At least 10 times increase
in the neurotensin transport across the BBB and a significant improvement in the analgesic
effect for pain control in three rat models of pain were reported. However, along with these
promising reports there were some discouraging results obtained using the angiopep-2
strategy for the brain delivery of a lysosome enzyme, arylsulfatase A (ASA) [290].
MTf—MTf, an iron-binding homolog of transferrin was initially recognized as a melanoma-
specific marker (also called melanoma tumor antigen P97) [291]. It was later detected in
other tissues including brain, where it is expressed by endothelial cells and activated
microglia in AD patients. Despite structural similarity to transferrin, MTf exists mainly in
membrane-bound form having a C-terminal glycosyl phosphatidylinositol anchor (25
residues) and two homologous extracellular domains (342 and 352 amino-acid residues). A
soluble form of MTf (sMTf) was detected in the blood at very low concentration.
Interestingly, i.v. injected sMTf accumulated in the brain although to a lesser extent than
transferrin [292]. Beliveau’s group and others demonstrated that recombinant human MTf
passed into the brain across BBB at a high rate via LRP1 receptor-mediated pathway [267,
293]. Owing to a very low level in the blood and fast rate of transcytosis across the BBB,
MTf could be used as a carrier for drug delivery to the brain. Indeed, Tang and colleagues
engineered a fusion protein of sMTf and cell surface coxsackie-adenovirus receptor (sCAR),
which binds as adaptor protein to both adenovirus serotype 5 (Ad5) and brain endothelium
receptor and promotes internalization of the Ad5 vector. Using an in vitro BBB model, these
authors demonstrated that sMTf-sCAR fusion protein redirects the cell trafficking of the
Ad5 vector and facilitates its transport across the brain endothelial cells [294]. Moreover,
sMTf was able to successfully deliver conjugated doxorubicin molecule to brain tumors in
vivo [295]. Similarly, sMTf-adriamycin conjugates crossed BBB and prolonged survival of
animals bearing intracranial gliomas or peripheral mammary tumors, compared to the
animals treated with the same cumulative dose of free-adriamycin [296]. BioMarin
Pharmaceuticals Inc. is currently developing sMTf as delivery modality for enzyme
replacement therapy in the brain [297].
RAP—RAP is a 39 kDa protein located mainly in endoplasmic reticulum where it plays
crucial role in assisting folding and trafficking of the LDL receptor family including LRP1
and LRP2. Upon i.v. administration RAP binds LDL receptor family and therefore inhibits
clearance of other ligands such as tPA [298, 299]. Pan and colleagues reported that RAP
crossed BBB and reached brain parenchyma via LRP2-mediated pathway at a higher rate
than transferrin and MTf [300]. Moreover, Prince showed that conjugation of RAP to
lysosome enzyme, IDUA and acid α-glucosidase enhanced enzymes intracellular
accumulation and substrate depletion within fibroblasts thus suggesting the possibility of
RAP use as a drug carrier [301]. However, therapeutic potential of RAP conjugates for
treatment of brain-related lysosome storage disease remains untested.
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5.5 Protein modification with hydrophilic and amphiphilic polymers
Perhaps the most successful approach to improvement of bioavailability of proteins is
PEGylation - covalent attachment of PEG polymer chains to protein molecules. Frank Davis
and Abraham Abuchowski reported the very first studies on protein PEGylation in 1970s.
Using catalase and albumin as model proteins, they discovered that attachment of PEG (1.9
or 5.0 kDa) improved protein circulation and serum stability and reduced immunogenicity
[302, 303]. Since then, PEGylation has been widely used to modify proteins and helped to
advance development of protein therapeutics tremendously [304]. Various aspects of
PEGylation, such as chemistry of PEGylation, analytic and bioanalytic characterization, the
PK and pharmacologic properties and the clinical applications are extensively discussed in
literature [180, 305–312]. PEGylation of proteins can prolong their blood circulation,
increase their serum stability, and reduce their immunogenicity [305, 310, 311, 313]. Peptide
agonists of the GLP-1 receptor are rapidly gaining attention as antidiabetic agents, since in
addition to increasing glucose-dependent insulin secretion, they also cause weight loss. For
example, oxyntomodulin (OXM), a natural peptide with sequence homology to both
glucagon and GLP-1, was recently modified with PEG to increase this peptide’s half-life
and decrease its degradation by dipeptidyl peptidase IV (DPP-IV) [314]. The PEGylated
OXM exerted an anti-hyperglycemic effect in diet-induced obese (DIO) mice in a glucose-
dependent manner, and thus has shown potential as novel once-weekly GLP-1 mimetic with
both glucose-lowering activity and weight loss efficacy. However, albeit PEGylation of
leptin increased this hormone’s half-life in circulation it did not improve its brain uptake in
animals. Moreover, PEGylated leptin failed to induce weight loss in obese patients.[315–
317] Therefore it appears that PEGylation is not successful as a brain targeting strategy. This
may be explained by increased molecular weight and hydrophilicity of PEGylated proteins,
both unfavorable for transport of proteins across cellular barriers. Therefore, albeit
PEGylation improves serum bioavailability of a protein and thus increases its exposure to
the brain capillaries these effects are offset by reduced permeability of PEGylated proteins
across the BBB [318, 319]. In addition to PEG some other hydrophilic polymers, such as
natural polysialic acid (PSA) [119], dextrin [320–323], and hyaluronic acid [324] as well as
synthetic N-(2-hydroxypropyl)-methacrylamide (HPMA) [325] were also used for protein
modification. Most of these protein-polymer conjugates have extended circulation time and
improved stability in serum as compared to native proteins. However, modification of
proteins with these hydrophilic polymers, like in the case of PEGylation, improves the PK
profile of proteins but not their ability to cross the physiological barriers.
The protein serum bioavailability and ability to penetrate across brain endothelium can be
improved by modification of proteins with amphiphilc block copolymers [225]. For
example, Pluronic block copolymers (also termed "poloxamers") consist of hydrophilic
poly(ethylene oxide) (PEO or PEG) and hydrophobic poly(propylene oxide) (PPO or
polypropylene glycol (PPG)) segments arranged in a basic A-B-A structure: PEO-PPO-PEO
(PEG-PPG-PEG). By changing the lengths of the PEO and PPO segments one can vary the
hydrophilic-lipophilic balance of these polymers and alter their ability to interact with each
other and lipid membranes. A characteristic of Pluronics is the ability to self-assemble into
micelles in aqueous solutions above the critical micelle concentration (CMC). Already a
quarter of century ago Pluronic micelles conjugated with antibodies to brain specific
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antigens (e.g. α2-GP) were shown to deliver solubilized compounds to the CNS after i.v.
administration in mice [326]. Interestingly, selected Pluronics are potent inhibitors of Pgp
and increase entry of Pgp-substrates into the brain across BBB [327–329]. These
copolymers were shown to cross membranes of BMECs and enter brain tissues in mouse
models [330, 331]. Moreover, some copolymers, such as Pluronic P85 were shown to
internalize in primary neurons [332]. These copolymers follow cell trafficking itinerary
similar that of cholera toxin B, including binding with cholesterol-rich domains in cell
membrane and then internalization via caveolae-mediated or caveolae- and clathrin-
independent endocytosis [333, 334]. Based on these observations Pluronics were used to
modify proteins to deliver them across the BBB. Initially, HRP modified with relatively
hydrophobic Pluronic block copolymers (P85, L81 and L121) was shown to cross in vitro
BBB model and following i.v. administration in mice, HRP-P85 exhibit higher permeability
at the BBB than HPR alone and accumulated in brain parenchyma [212, 335]. Subsequently,
SOD1 modified with Pluronic P85 or L81 was shown to internalize into neuronal cells,
while retaining enzymatic activity and acting as a scavenger of intracellular superoxide
induced by angiotensin II [336]. Moreover, after intracarotid administration in rabbits this
conjugate also induced a central physiological response by inhibiting angiotensin II-induced
increase in the arterial pressure, not observed after native SOD1 injection [337].
Protein modification with Pluronics was used recently for development of an anti-obese
drug on the base of leptin [78, 338, 339]. Leptin, a candidate for the treatment of epidemic
obesity, has failed in part because of impairment in its transport across the BBB that
develops with obesity [340–342]. It was suggested that modification of leptin with Pluronic
P85 might permit this protein to penetrate the BBB independently of its transporter, thereby
overcoming peripheral leptin resistance. PK studies demonstrated that Pluronic conjugate
was transported across BBB at an influx rate similar to native leptin, but via non-saturable
mechanism independent of leptin transporter [338]. Importantly, the conjugate reduced food
intake following i.c.v. or i.v. administration in healthy mice and in mouse models of obesity
(ob/ob, and diet-induced obese mouse) [338, 339]. We further generated two new leptin-P85
conjugates: one, Lep(ss)-P85(L), containing one P85 chain and another, Lep(ss)-P85(H),
containing multiple P85 chains. Lep(ss)-P85(L) crosses the BBB using the leptin transporter,
and exhibits improved peripheral PK along with increased accumulation in the brain
compared to unmodified leptin. Lep(ss)-P85(H) also has improved peripheral PK but in a
striking difference to the first conjugate penetrates the BBB independently of the leptin
transporter via a non-saturable mechanism. The results demonstrate that leptin analogs can
be developed through chemical modification of the native leptin with Pluronic P85 to
overcome leptin resistance at the level of the BBB, thus improving the potential for the
treatment of obesity [339].
Although the use of Pluronics for brain delivery of proteins is still under investigation, the
translation of this technology to a clinic is promising. One advantage of using Pluronics for
brain delivery is their relatively low toxicity. Pluronic copolymers are FDA-approved
excipients and are widely used in a variety of clinical applications. No CNS related toxicity
was reported in Phase I and II clinical trials of doxorubicin formulated with Pluronics
("SP1049C") [343, 344]. Studies show that Pluronics at concentrations substantially
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exceeding those used in protein-Pluronic conjugates have little if any toxic effect on brain
endothelial cells in vitro and in vivo and do not alter paracellular permeability of BBB [327,
328, 345].
Another technology showing potential is protein modification with amphiphilc poly(2-
oxazoline)s (POx) block copolymers [346]. POx polymers have been explored in various
drug delivery and other biomedical applications [347–357]. Their advantages compared to
PEG and Pluronics include greater stability, greater synthetic versatility allowing
introduction of various functionalities both the polymer repeating units and terminal groups.
This makes them promising candidates for protein brain delivery. Hydrophilic POx
homopolymers such as poly(2-methyl-2-oxazoline) (PMeOx) and poly(2-ethyl-2-oxazoline)
(PEtOx) are considered as alternatives to PEG in applications similar to PEGylation [358,
359]. The amphiphilic POx block copolymers exhibit relatively low cytotoxicity and can
transport into cells similarly to Pluronics [356, 357]. We have reported recently that HRP
modified with amphiphilic block copolymers of PMeOx and 2-butyl-2-oxazoline (P(MeOx-
b-BuOx), or PEtOx and 2-butyl-2-oxazoline (P(EtOx-b-BuOx) transported into intracellular
compartments in both MDCK and Caco-2 cells [360]. Next, we modified SOD1 with two
aforementioned POx block copolymers [361]. Similar to SOD1-Pluronic conjugates, SOD1-
POx conjugates retained high stability and catalytic activity after modification. Moreover,
SOD1-P(EtOx-b-BuOx) conjugate showed high uptake level in CATH.a neurons and
efficiently scavenged intracellular superoxide induced by Ang II stimulation. This conjugate
utilized caveolae-mediated and/or clathrin and caveolae-independent endocytosis for cell
entry. After i.v. administration in mice radiolabeled SOD1-P(EtOx-b-BuOx) displayed
longer blood half-life compared to native SOD1, crossed BBB by non-saturable mechanism,
and reached brain parenchyma [361]. Even though this new technology has already shown
potential in enhancing delivery of proteins to the brain, a clear understanding of POx and
protein-POx interactions with brain endothelium is needed to take the full advantage of the
structural versatility of this type of polymer.
6. Particle-based carriers for CNS delivery of proteins
Numerous studies have shown that encapsulation of therapeutic proteins in nano- or micron
size particles decreases protein immunogenicity and improves protein stability and
circulation time (Figure 4). Liposomes and PLGA nanoparticles are possibly the most
extensively investigated types of carriers for protein delivery. Other systems investigated in
the context of CNS delivery include poly(butylcyanoacrylate) (PBCA) nanoparticles, and
more recently, polyion complexes. Some other materials such as PEG-silica,
bolaamphiphilies, chitosan, PEG-polylactide (PLA), PEG-poly(ε-caprolactone) (PCL) and
PLA-D-α-Tocopheryl polyethylene glycol succinate (TPGS) were also evaluated for brain
delivery [283, 371–377]. Unfortunately, such particle-based carriers generally do not cross
BBB. Surface modification with specific brain targeting moieties may provide opportunities
to enhance brain the delivery of particles but the effectiveness remains questionable [378–
380]. Nevertheless interest in particle-based systems for delivery of therapeutic agents to
CNS persists due to ongoing efforts in application of these systems with drugs having a
peripheral mode of action. Notably, majority of such studies using particle-based carriers
involve delivery of low molecular mass therapeutics to the CNS [381, 382], with only
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relatively few examples reporting CNS delivery of proteins [383]. Because most carrier-
based technologies were originally developed for delivery of low molecular mass drugs, in
some cases there is an additional challenge in modifying the carrier technology to facilitate
protein formulation, ensure high protein loading and stability. Below we consider some of
these carries and their applications for protein delivery to the brain.
6.1 Liposomal carriers
Liposomes have been extensively investigated as carriers for delivery of small drugs,
proteins, DNA, siRNA and imaging agents [384–387]. Few of these studies involved
delivery of proteins to the brain. For example, over 30-years ago it was reported that
encapsulation of proteins (β-galactosidase, thyrotrophin-releasing hormone (TRH)) in
neutral (phosphatidylcholine (PC), cholesterol (Chol)) or anionic (PC, Chol,
dicetylphosphate or phosphatidylserine (PS)) liposomes can increase brain accumulation of
these proteins after i.v. administration [388, 389]. Interestingly, TRH loaded in neutral
liposomes showed greater brain uptake and physiological effect (rise in body temperature)
than TRH in anionic liposomes. Incorporation of TRH in cationic liposomes (PC, Chol and
stearylamine) also increased the protein brain uptake. However, stearylamine caused
epileptic seizures and cerebral tissue necrosis this and therefore, due to toxicity this
formulation was not pursued [389]. Nevertheless, cationic liposomes were further used to
deliver SOD1. Several studies demonstrated that SOD1 formulated in cationic liposomes
administered i.v. can reduce cerebral infarct volume size in ischemic stroke and brain trauma
animal models [390–393]. Though reasons for the improved brain delivery of the liposome-
incorporated proteins remained unknown, it was speculated that liposome could cross-
lipophilic membranes of brain endothelial cells [389]. To the best of our knowledge no
evidence of that has been provided so far to support this mechanism. It was also suggested
that cationic liposomes can produce a transient pathologic opening of the BBB during
experimental stroke, which can explain at least some of the effects observed [394, 395].
Overall, the translation of cationic liposomes to practical use has been hindered due to their
low stability and potential toxicity in vivo [396, 397].
Some of the early work using liposomes of different sizes (40–80 nm, <1 µm, >5 µm, and up
to 40 µm) and compositions (Chol/PC, mouse brain homogenates lipids, PC/PS; dioleoyl
phosphatidylethanolamine (DOPE) and N-succinyldioleoylphosphatidylethanolamine
(SOPE)) failed to show liposomes uptake into the brain in healthy mice or mice with
experimental brain metastases [398, 399]. The larger µm-sized liposomes were retained at
the BBB possibly fusing with the membranes of endothelial cells and causing embolism and
high pressure within the brain, especially in animals with experimental tumors [398, 399].
Interestingly, one of these studies implied that circulating blood monocytes could
phagocytose liposomes and deliver them to the brain since these cells were shown to invade
experimental metastases even in animals with an intact BBB [398].
It is well known that many liposomes are rapidly cleared from circulation by the
reticuloendothelial system, which could decrease the exposure of such liposomes to the BBB
after parenteral administration. The immunogenicity of liposomes has also been a concern.
Incorporation of PS or phosphatidylinositol in the lipid bilayer in protein-containing
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liposomes can stabilize liposomal formulations, prevent the premature protein release in
serum and reduce the immunogenicity [400–402]. Decreasing the liposome particle size (<
100 nm) and PEGylation of the liposome surface can also extended the liposomes
circulation time. However, such modifications also can reduce liposome interactions with
the brain endothelium and neuronal cells thereby hindering delivery of liposomal drugs to
the brain. To increase delivery of PEGylated liposomes to the brain, one can modify
liposomes with brain-specific ligands that can be internalized and transcytosed across the
brain endothelium. For example, modification of the surface of the PEGylated liposomes
with transferrin enhanced cellular uptake of the liposomes and delivery of the liposome-
encapsulated protein (HRP) in the brain capillary endothelial cells [378]. In an animal study
PEGylated liposomes functionalized with brain-targeting ligand, RMP-7 were shown to
carry NGF to the brain [379]. Another example of targeted liposomes is so-called “pro-
cationic liposomes” modified with a cationic ligand lactoferrin (LF), which targets receptors
in brain endothelium [403]. Such modified liposomes were shown to enter the primary rat
brain endothelial cells through a combination of adsorptive and receptor-mediated
endocytosis. After i.v. administration these liposomes can deliver an encapsulated anticancer
agent, doxorubicin to a glioma in a mouse model [404]. In spite of all these findings, the
ability of brain targeting moieties to improve liposome delivery to the brain might be
questionable. Most of these studies provided evidence using in vitro brain endothelial cells.
Moreover, most of the animal studies available have not reported brain PK parameters
(influx rate, serum half-life etc.) that are essential for evaluation of protein brain delivery
outcomes. As a result the interpretation of the effects of some brain targeting moieties can
be challenging. For example, one study reported that several brain specific moieties such as
angiopep-2, COG133 and CRM197, did not show any improvement in targeting liposomes
to the brain in vitro and in in vivo [380]. Nevertheless, targeting via nutrient transporters
expressed at the BBB has been also used to increase brain uptake of liposomes. For
example, liposomes modified with reduced glutathione (GSH) have been used as a targeted
carrier for delivery of low molecular mass drugs like ribavirin [405], methylprednisolone
[406], doxorubicin [407] and an opioid peptide [408]. GSH-liposomes showed higher brain
uptake upon i.v. injection in normal rats and in rat model of MS compared to non-targeted
liposomes and free drug/peptide, respectively [406, 409]. The i.v. injection of
methylprednisolone in GSH-liposomes decreased the clinical score of neurological
aberrations in a rat model of MS [406]. GSH-liposomes encapsulating an opioid peptide
showed an improved PK profile compared to the free drug in a rat microdialysis study [408].
GSH-PEG modified Doxil® liposomes showed a small but significant increase (compared to
non-targeted Doxil® liposomes) in plasma drug concentrations 4 days after i.v. injection in
mice; however, drug concentration in the brain was not significantly improved.
Nevertheless, these targeted liposomes showed a safety profile similar to Doxil®, decreased
brain tumor volume and resulted in a marginal but significant increase in survival time
compared to saline and non-targeted Doxil® liposomes in a mouse model of gliablastoma
multiforme. Brain delivery of GSH-liposomes was also evidenced using tracer dye
carboxyfluorescein as a cargo [410]. The cellular uptake of the dye in rat brain endothelial
cells was increased when incorporating to GSH-liposomes compared to that of non-targeted
liposomes. Moreover, rat brain microdialysis studies after i.v, injection of GSH-liposomes
showed a small but statistically significant increase in the dye concentrations in the brain
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extracellular fluid 6 hrs post-injection compared the non-targeted liposomes. However, to
the best of our knowledge the GSH-liposomes have not been used for protein delivery to
CNS so far.
In addition to a traditional parenteral delivery route liposomes were also administered
intranasally. For example, Migliore and colleagues developed cationic liposomal
formulation loaded with a model protein, ovalbumin for intranasal delivery [411]. This
formulation resulted in elevated brain delivery of encapsulated ovalbumin concentrations in
brain compared to delivery of the free protein [411].
Overall, studies on liposomal carriers for protein therapeutics for neurologic diseases have
presented conflicting evidence of brain delivery and safety and faced many challenges
associated with encapsulation procedures, loading capacity, and preserving protein activity.
6.2 PLGA particles
PLGA and its derivatives are used to make perhaps the most widely studied nano/micro-size
particles for encapsulation of therapeutic proteins. Advantages of these polymers include
their biocompatibility and biodegradability as well as suitability for design of sustained-
release protein formulations. The release rates of encapsulated proteins can be tuned by
varying the lactic acid to glycolic acid molar ratio and the polymer molecular mass [412].
On the flip side, disadvantages of PLGA carriers include initial “burst” release, irreversible
adsorption of proteins to the polymer matrix, as well as inactivation of proteins during
preparation, storage and application including effects of products of PLGA degradation,
lactic and glycolic acids, on protein stability [413]. Blending with other polymers or
excipients, stabilizing proteins during encapsulation by adding zinc or antacid excipients and
other means may improve protein stability, loading and release profile [414].
In spite of its extensive use for protein delivery, no direct brain PK data is available showing
that PLGA particles improve uptake of encapsulated proteins in the brain. However, a
sustained release of proteins from PLGA carriers could benefit the treatment of chronic
brain diseases. Indeed, subcutaneous injection of PLGA microspheres containing insulin-
like growth factor I (IGF-I) restored the motor function and increased the survival in mice
with inherited Purkinje cell degeneration disease [415]. IGF-I was continuously released
from the microspheres, which likely increased the brain levels of IGF-I over a period of time
and resulted in therapeutic effects similar to a continuous subcutaneous infusion of IGF-I
[415, 416]. Another study reported a sustained release for up to 60 days of a therapeutic
protein, BDNF from PLGA-poly( L-lysine)-PEG microspheres [417]. Although in vivo test
was not reported, the bioactivity of the released BDNF was confirmed by cell proliferation
and neurite outgrowth in pheochromocytoma PC12 cells stably expressing BDNF cognate
receptor TrkB [417].
Interestingly, intracarotid (i.c.) injection of SOD1 encapsulated in PLGA nanoparticles
significantly reduced brain infarct volume and prevented neuronal cell death in a rat model
of transient ischemic stroke [396]. This study compared 3 different administration routes:
i.c., i.v. (via the tail and jugular veins) and demonstrated that i.c. route resulted in a 13-fold
greater brain uptake of the enzyme compared to the i.v. routes. The observed
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neuroprotection could be a result of a sustained release of active SOD1 from nanoparticles,
which accumulate in the brain due to the BBB impairment typical of ischemia-reperfusion
model.
Like in the case of other carriers, the PLGA nanoparticles can be decorated with brain
targeting moieties. For instance, PLGA nanoparticles modified with similopioid peptide
were shown to deliver their payload to the brain after i.v. administration in rats [418, 419].
Notably, the nanoparticles modified with a scrambled peptide did not accumulate in the
brain, suggesting involvement of a similopioid peptide-related brain uptake mechanism
[420]. The targeted nanoparticles loaded with a low molecular mass drug, loperamide
produced central antinociceptive effect in rats, comparable to the effects of this drug,
administered i.c.v.. Another study used PLGA nanoparticles decorated with similopioid
peptide and sialic acid residues, which target sialic acid receptor in brain parenchyma [421].
However, this modification in addition to increased accumulation of the nanoparticles in the
brain also appeared to increase their accumulation in peripheral tissues.
Targeting strategies is commonly combined with PEGylation of the nanoparticle surface in
an attempt to increase the nanoparticle circulation time and decrease interactions with non-
targeted cells. Thus, PEGylated PLGA nanoparticles decorated with tetanus toxin fragment
C (a neuron-binding motif) were selectively taken up by neuroblastoma cells but not in
hepatocellular carcinoma and BMECs, however, no in vivo studies were reported [422]. The
PEGylated PLGA nanoparticles conjugated with cationized BSA delivered and released
their cargo, 6-coumarin in the brain after caudal vein administration in mice [423]. As is
evident from this discussion, most of these studies reported the use of the targeted
nanoparticles for the delivery of low molecular mass solutes. However, there are some
examples of targeted nanoparticles for the brain delivery of oligo- and polypeptides. For
example, PEGylated PLGA nanoparticles decorated with lactoferrin were shown to deliver
neuroprotective peptides including S14G-humanin and urocortin to the brain and induce
neuroprotective effects in animal models of AD and PD [424, 425]. Overall, although these
observations appear encouraging, numerous questions including PK and evidence of brain
delivery and release of proteins, as well treatment associated toxicities, in particular
immunogenicity of the ligand coated particles, would need to be thoroughly addressed in
most cases before a possibility of clinical translation of these systems could be discussed.
6.3 PBCA nanoparticles
Kreuter and colleagues evaluated PBCA nanoparticles coated with non-ionic surfactants
(polysorbate 80, Pluronic F68) for CNS delivery of a variety of low molecular mass drugs
such as doxorubicin, loperamide, tubocurarine, NMDA receptor antagonist MRZ 2/576, and
peptides such as dalargin and kytorphin [426]. Later on these nanoparticles were also used to
deliver proteins. For example, one study suggested increased brain uptake of NGF and
reduced PD symptoms after i.v. administration of NGF-loaded polysorbate 80-coated PBCA
nanoparticles in a mouse model of PD [383]. Similarly, Lin and colleagues reported that
polysorbate 80-coated PBCA nanoparticles loaded with HRP or enhanced green fluorescent
protein (EGFP) can deliver these proteins to the brain in a rat model of TBI [427]. Another
study evaluated dextran and polysorbate 80-coated PBCA nanoparticles carrying covalently
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immobilized SOD1 and anti-glutamate N-methyl D-aspartate receptor 1 antibody [428].
These protein-PBCA conjugates were shown to prevent neuronal cell death mediated by
superoxide radicals O2·– toxicity in the rat cerebellar cells. No animal study was reported in
this work.
The enhanced brain delivery was also observed in PEGylated cyanoacrylate nanoparticles
coated with polysorbate 80 [429]. However, not all nanoparticles with polysorbate 80
coating showed enhanced brain delivery. For example, polystyrene nanoparticles coated
with polysortabe 80 did not deliver any dalargin cargo into the brain [430]. Instead of brain
accumulation, polysorbate 80-coated poly(methylmethacrylate) nanoparticles mainly
accumulated in the liver [431]. Olivier and colleagues reported a fast cargo release from
PBCA nanoparticles in serum likely caused by polysorbate 80, serum protein competition
and rapid nanoparticle degradation in the blood [430, 432].
The brain entry mechanism of PBCA nanoparticles after their i.v. administration is still
unclear. It is hypothesized that surfactant-coated PBCA nanoparticles adsorb apolipoprotein
E (ApoE) or apolipoprotein B (ApoB) from the bloodstream and cross BBB by LRP-
mediated transcytosis [433]. ApoE is a 35 kDa glycoprotein lipoproteins component that
plays a major role in the transport of plasma cholesterol in the bloodstream and CNS [434].
Its non-lipid related functions including immune response and inflammation, oxidation and
smooth muscle proliferation and migration [435]. Published reports indicate that some
nanoparticles such as human albumin nanoparticles with covalently-bound ApoE [436] and
liposomes coated with polysorbate 80 and ApoE [437] can take advantage of ApoE-induced
transcytosis. Although no studies provided direct evidence that ApoE or ApoB are
responsible for brain uptake of the PBCA nanoparticles, the precoating of these
nanoparticles with ApoB or ApoE enhanced the central effect of the nanoparticle
encapsulated drugs [426, 433]. Moreover, these effects were attenuated in ApoE-deficient
mice [426, 433]. Another possible mechanism of transport of surfactant-coated PBCA
nanoparticles to the brain is their toxic effect on the BBB resulting in tight junction opening
[430]. Therefore, in addition to uncertainty regarding brain transport mechanism of PBCA
nanoparticle, cyanocarylate polymers are not FDA-approved excipients and have not been
parenterally administered to humans.
6.4 Block ionomer complexes (BIC)
BIC (also called “polyion complex micelles”) are a promising class of carriers for the
delivery of charged molecules developed independently by Kabanov’s and Kataoka’s groups
[438, 439]. They are formed as a result of the polyion complexation of double hydrophilic
block copolymers containing ionic and non-ionic blocks with macromolecules of opposite
charge including oligonucleotides, plasmid DNA and proteins [438, 440–443] or surfactants
of opposite charge [444–449]. Kataoka’s group demonstrated that model proteins such as
trypsin or lysozyme (that are positively charged under physiological conditions) can form
BICs upon reacting with an anionic block copolymer, PEG-poly(α, β-aspartic acid) (PEG-
PAA) [440, 443]. Our initial work in this field used negatively charged enzymes, such as
SOD1 and catalase, which we incorporated these into a polyion complexes with cationic
copolymers such as, PEG-poly( ethyleneimine) (PEG-PEI) or PEG-poly(L-lysine) (PEG-
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PLL). Such complex forms core-shell nanoparticles with a polyion complex core of
neutralized polyions and proteins and a shell of PEG, and are similar to polyplexes for the
delivery of DNA. Advantages of incorporation of proteins in BICs include 1) high loading
efficiency (nearly 100% of protein), a distinct advantage compared to cationic liposomes
(~32% for SOD1 and ~21% for catalase [450]; 2) simplicity of the BIC preparation
procedure by simple physical mixing of the components; 3) preservation of nearly 100% of
the enzyme activity, a significant advantage compared to PLGA particles. The proteins
incorporated in BIC display extended circulation time, increased uptake in brain endothelial
cells and neurons demonstrated in cell culture and increased stability in cells [451]. Our
laboratory has demonstrated that BIC-incorporated butyrylcholinesterase (BChE) can be
delivered to the brain in BChE−/− mice. Interestingly, the delivery of BChE appeared to be
more efficient when the BIC was administered i.m. compared to the i.v. administration
[452]. We speculate that BIC administered i.m. could be delivered to the brain via
neuromuscular junctions by retrograde transport. In addition, we also developed and
characterized several generations of BIC formulations ("nanozymes") of two antioxidant
enzymes, SOD1 and catalase and evaluated them in several animal models [451, 453, 454].
For example, a covalently stabilized, cross-linked (cl) nanozyme formed by SOD1 and PEG-
PLL exhibited improved stability in blood and brain and increased uptake in both brain
capillaries and parenchyma, as compared to non-cl nanozymes and native protein [453]. The
single dose of this nanozyme after i.v. administration resulted in a decreased infarct volume
and improved sensorimotor outcomes compared to untreated (saline-injected) and native
SOD1 groups in a rat model of transient cerebral ischemia-reperfusion injury. One should
expect further developments in evaluation of this new technology for the delivery of proteins
to the CNS.
6.5 Cell-mediated delivery of nanoparticles
A relatively new approach to CNS protein delivery involves loading of protein-incorporated
BIC in immune response cells that respond to pathological inflammation and migrate to the
brain tissue thereby serving as conduits for protein delivery [455] (Figure 5). Batrakova and
colleagues have investigated this paradigm as a potential strategy for the delivery of
therapeutic antioxidant enzymes to treat PD in a series of studies [456–462]. To protect
enzymes from degradation in the carrier cells they incorporated these enzymes in the BIC.
For example, they loaded catalase-PEI-PEG nanozymes (60–100 nm in diameter) into bone-
marrow derived macrophages (BMM) and administered these macrophages i.v. in a mouse
model of PD. Nearly 0.5% of protein delivered this way with the BMM accumulated in the
brain tissue, which was several fold improvement in brain delivery compared to the
nanozymes directly injected in the mouse [462]. The attenuation of PD manifestations
(microglial activation and astrocytosis) in animals treated with nanozyme-loaded BMM was
also reported, which was not much different from animals injected with the nanozyme alone
[462]. The nanozyme-loaded BMM also increased survival of dopaminergic neurons and
rescued the loss in the N-acetyl aspartate (used a measure to determine neuroprotection),
which suggested the neuroprotective effects. The optimization of the nanozyme formulation
for this delivery strategy was also reported [463]. The PK and biodistribution studies
demonstrated that nanozyme-loaded BMM had increased area under the curve (AUC), half-
life and mean residence time in blood circulation, and greater bioavailability, compared to
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nanozyme alone. Enhanced brain delivery of nanozyme loaded in BMM was also
demonstrated [464]. However, AUC was also increased (ranging from 1.8 to 4.6-fold) in the
non-target organs such as liver, spleen and kidney in addition to the brain tissue. A brain
influx rate of 0.026 µL/g.min was determined for nanozyme-loaded BMM, which was 1.9-
fold higher than for nanozyme alone. Recent study also suggested that BMM facilitated
transport of nanozyme form to brain endothelial, glial and neuronal cells through multiple
endocytosis-independent pathways such as transient intercellular connections, macrophage
bridging conduits and exosomes [465, 466]. Altogether these studies may open new avenues
for cell-mediated protein delivery to the brain. Interested readers are referred to a recent
review for a comprehensive overview [467].
7. Conclusion
Developing protein therapeutics for treatment of CNS disorders is an unmet need. A variety
of delivery strategies discussed in this review have shown promise to delivery proteins to the
brain. The most advanced in clinic are the strategies involving direct delivery of proteins to
the CNS using the central administration routes, i.c.v. and intraparenchymal, as well as i.t.
administration. Recently intranasal administration in the vicinity of nasal cribriform plate,
which allows substances to bypass the BBB and enter the brain directly with minimum
serum exposure, has gained increasing attention. There appears to be a significant room for
advancement of these strategies by combining them with the protein delivery approaches,
which were previously explored mainly in the context of the parenteral administration.
Modification of proteins with cationic moieties, CPP, fatty acid residues, brain-targeting
moieties and amphiphilic block copolymers can result in alteration of protein peripheral PK
and increase in the permeability of these proteins at the BBB. Numerous studies demonstrate
increased protein uptake in the brain and in some cases increased therapeutic efficacy in
relevant CNS disease models. However, the mechanisms of transport of the modified
proteins across the BBB in most cases are not well understood. Moreover, there are safety
issues associated with most delivery approaches especially the use of cationic moieties and
CPP. In contrast, modification of proteins with fatty acids and amphiphilic block
copolymers, appear to be promising and in particular, fatty acylation has already reached a
clinical stage, although toxicology profiles should be carefully evaluated in each case. Much
insight on the mechanism of CNS delivery has been obtained in studies of the PK,
pharmacodynamics and toxicity of low affinity antibodies against TfR. In contrast, CNS
delivery of proteins using particle-based carriers, in particular, liposomes or PLGA particles
appears to be less advanced and less effective. Decorating the particle surface with
appropriate molecules that can target receptors at the brain endothelium is one way to
address this problem but the available results are still contradictory. Nevertheless,
investigating novel nanoparticles to deliver protein to the brain certainly represents a future
direction especially in the context of nontraditional delivery approaches avoiding the BBB,
intranasal administration and delivery using cells as carriers.
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Ab-InsR antibodies against insulin receptor
Ab-TfR antibodies against transferrin receptor
AD Alzheimer’s disease
Aerosol OT bis-(2-ethylhexyl) sulfosucciate




AUC area under the curve
α2-GP α2-glycoprotein
Ab-BACE1 antibodies against β-secretase
BBB blood-brain barrier
BDNF brain-derived neurotrophic factor
BIC block ionomer complexes
BChE butyrylcholinesterase
bFGF basic fibroblast growth factor
BMECs brain microvessel endothelial cells
BMM bone-marrow derived macrophages
CED convection-enhanced delivery
Chol cholesterol
CMC critical micelle concentration





DPP-IV dipeptidyl peptidase IV
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GDNF glial cell-derived neurotrophic factor
GFAP gliofibrillar acid protein
GLP-1 glucagon-like peptide 1
GSH reduced glutathione
EAE experimental autoimmune encephalomyelitis
ECS extracellular space
EGF epidermal growth factor
EGFR EGF receptor
ERT enzyme replacement therapy
FDA Food and Drug Administration
FGF fibroblast growth factor
HAD HIV-1-associated dementia












KLH keyhole limpet hemocyanin
LDL low-density lipoprotein
LRP1 ligand of LDL receptor-related protein 1
LRP2, LRP1 ligand of LDL receptor-related protein 2
LSDs lysosomal storage disorders
M6P mannose 6-phosphate
MCAO middle cerebral artery occlusion model
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MPS I mucopolysaccharidosis I
MPS II mucopolysaccharidosis II
MS multiple sclerosis

























RAP receptor associated protein
RDP Rabies virus glycoprotein-derived peptide
rhIDU α-L-iduronidase
sCAR cell surface coxsackie-adenovirus receptor
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TAT trans-activating transcriptional activator
TBI traumatic brain injury
TJ tight junctions
TfR transferrin receptor
TNFR tumor necrosis factor decoy receptor
TPGS α-tocopheryl polyethylene glycol succinate
VLDL very-low-density lipoprotein
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Figure 1. BBB and NVU in physiological and pathological conditions
In normal CNS brain microvessel endothelial cells (BMECs) are sealed by tight junction
(TJ). They are surrounded at the apical side by a thin basement membrane (BM), which also
surrounds the pericytes adjacent to BMEC. Along with astrocytes, microglia and neurons,
these cells comprise the neuron vascular unit (NVU). During the disease progression, the TJ
can be disrupted and BBB breached [51], BM degraded [30], immune cells migrate from
blood to brain, microglia abnormally activated [32], pinocytosis and transcytosis intensified
[52, 53], and inwardly and outwardly transporters of various substances modified.
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Figure 2. Administration routes of protein therapeutics for CNS delivery
Early approaches to CNS protein delivery involved common parenteral injection via
intramuscular, intravenous, and subcutaneous routes. In these cases proteins are ultimately
distributed within systemic vasculature including brain capillaries. Therefore, brain entry of
proteins following parenteral administration requires crossing the BBB. Central
administration routes such as intraparenchymal and intracerebroventricular allow bypassing
the BBB. Intrathecal administration has been used as a less-invasive alternative to central
administration. Intranasal route has been recently explored as a minimally invasive delivery
strategy allowing to bypass the BBB. It opens up a new avenue since drug administration at
the level of the nasal cribriform plate can facilitate brain delivery with minimal serum
exposure.
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Figure 3. CNS Delivery of Proteins by Chemical Modification
(A) Cationization: Chemical modification of a protein’s carboxylic acid groups with natural
or synthetic amines has shown to improve cellular uptake and delivery of the cationized
protein into the brain parenchyma. (B) Fusion protein constructs with CPPs: CPPs are
peptides composed of basic amino acid residues that are believed to traverse across cell
membranes thus resulting in intracellular delivery of the attached cargo. (C) Fatty acid
acylation: This strategy involves modification of proteins with fatty acid residues that
increase proteins membrane binding and subsequent cellular uptake. (D) Conjugation with
brain targeting ligands: This strategy involves conjugation of protein of interest with
antibodies or ligands of receptors expressed on the brain endothelium that provide for active
transport of the conjugates to the brain. (E) Modification with amphiphilic polymers.
Pluronic and poly(2-oxazoline) block copolymers have been successfully used to modify
proteins to improve their peripheral pharmacokinetic properties and their uptake in the brain
parenchyma.
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Figure 4. Particulate Carriers for CNS delivery of Proteins
Liposomes are one early strategy used for delivery of proteins. They have been modified
with PEG to increase blood circulation time as well as targeting ligands to increase cellular
uptake at the brain endothelium. PLGA micro- and nanoparticles have been extensively
studied for protein delivery. Their unique advantages include biodegradability and
possibility to be used as sustained release formulations. PEGylated PLGA nanoparticles
were modified with targeting moieties to improve delivery to the brain. PBCA
nanoparticles coated with non-ionic surfactants were shown to deliver low molecular mass
drugs and proteins to the brain albeit the mechanism of their delivery to the brain is not
understood. BIC are formed by facile self-assembly of charged proteins and block ionomers
of opposite charge. The advantages of this strategy include ease of formulation, high loading
efficiency and capacity and retention of protein activity in BIC. Albeit in early stage of
investigation this strategy has shown promise in several animal models of disease. Cell-
mediated nanoparticle delivery is a novel approach that has been successfully
demonstrated for delivery of catalase BICs to treat PD in animal models. This strategy
involves loading of BICs into the immune cells that respond to pathological inflammation
and migrate to the brain tissue thereby facilitating drug delivery.
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Figure 5. Cell-mediated nanoparticle delivery to the brain
Bone marrow-derived macrophages are ex vivo loaded with nanozymes and administered
i.v. into bloodstream. They reach sites of inflammation in the brain, extravasate into the
brain parenchyma and transfer the nanoparticles into brain cells by either 1) directly
transducing surrounding cells (neurons) through cell-cell contacts (e.g. via filopodia) and/or
2) releasing exosomes containing repackaged nanozymes into extracellular space, followed
by the exosomes internalization into brain cells.
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